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ABSTRACT

Jackson, Matthew J. Ph.D., Purdue University, December 2015. Dissolution Behavior of
Amorphous Solid Dispersions. Major Professor: Lynne S. Taylor.

Current drug discovery techniques tend to identify potential new drug entities
with more complex structures which may pose significant formulation challenges. In
particular, an increasingly large number of new drug compounds have extremely poor
solubility in water, impacting the bioavailability of the drug. Solubility enhancement
techniques, such as amorphous solid dispersions (ASDs), can be used in oral dosage
forms to increase the apparent solubility of the drug in the gastrointestinal tract thus
increasing the bioavailability of the drug. However, the drug solution generated from the
dissolution of an ASD formulation is supersaturated. In other words, the solution
concentration is higher than the crystalline solubility. These solutions are therefore
thermodynamically unstable and can crystallize. Recent evidence suggests that some
systems can undergo another phase transformation prior to crystallization, namely liquidliquid phase separation (LLPS). LLPS creates a discrete drug-rich phase dispersed in the
continuous aqueous drug-lean phase and is expected to impact the bioavailability of the
drug though effects on diffusion and crystallization behavior. Currently there is a lack of
understanding of the mechanisms underlying the complex phase behavior of these
supersaturated solutions of poorly water soluble drugs, crucial to the formulation of

xx
amorphous solid dispersions. The work presented within this thesis is focused on
developing the techniques necessary for studying complex phase behavior through the
investigation of a model drug system. The relationship between amorphous solubility
and supersaturation was examined and correlated to the dissolution of amorphous solid
dispersions. The ability to predict, evaluate, measure, and understand supersaturated drug
solutions and the associated phase transitions, specifically LLPS and crystallization, is
critical to the formulation and overall effectiveness of ASDs.

1

CHAPTER 1. INTRODUCTION

1.1

Pharmaceutical Significance and Objective

Innovation and advances in drug discovery lead to exciting new molecular entities
(NMEs) every day.

These chemically complex NMEs are increasingly difficult to

formulate and frequently have suboptimal solubility and permeability. To aid in the early
development process, the Biopharmaceutics Classification System (BCS) was developed
to highlight the major factors impacting oral bioavailability. The system categorizes
molecules into one of four classes based on aqueous solubility (necessary for proper
dissolution within the gastrointestinal (GI) tract) and permeability (necessary for proper
uptake from the GI tract into the blood circulation).1 In recent years, there has been a
dramatic increase in NMEs with poor solubility, designated as BCS Class II and Class IV
molecules (Class II - good permeability or Class IV - poor permeability). Class II and IV
drugs make up roughly 40% of current drugs available on the market while nearly 90% of
NMEs in development are categorized as either Class II or Class IV.2 Thus, overcoming
the poor solubility hurdle is becoming an increasingly pressing issue.
The need to increase the solubility of new drugs to achieve adequate oral
bioavailability has led to the development of many novel solubility enhancement
techniques for formulation such as salts, co-crystals, lipid formulations, complexation,
nanoparticles, co-solvents, and amorphous solid dispersions.3 All of these formulation

2
approaches have their own benefits and limitations, but amorphous solid dispersions are
increasingly being viewed as the approach of choice for increasing the bioavailability of
poorly soluble drugs.4, 5
Amorphous formulations offer some additional advantages such as retaining the
original chemical entity, minimizing the addition of other molecules within the
formulation, and the potential to administer lower doses4.

These formulations also

present a number of obstacles including issues with physical stability (crystallization) of
the solid dosage form, manufacturability, and the formation of an unstable supersaturated
solution following dissolution.6 While a large body of research addresses the solid state
physical stability and manufacturing of amorphous solids dispersions, mechanistic and
kinetic understanding of the phase behavior of the supersaturated solutions created from
the dissolution of amorphous solid dispersions is lacking.
There is mounting evidence that there are multiple phase transitions that can occur
within highly supersaturated solutions of poorly water soluble hydrophobic drugs. Very
highly supersaturated solutions are thermodynamically unstable and thus will undergo
phase transitions to reduce their free energy. Liquid-liquid phase separation (LLPS),
crystallization, and amorphous precipitation have all been observed when evaluating
various drug systems.7-10 Such phase behaviors have been evaluated in other contexts
(e.g. industrial crystallization) and are intrinsically linked. Recognizing the issues
involved in creating thermodynamically unstable solutions from the dissolution of ASDs
will allow for a broader range of amorphous formulations of NMEs. The objective of this
research was to analyze and characterize the complex phase behavior of supersaturated
solutions of poorly water soluble compounds generated upon dissolution of an ASD.

3
1.2

The Crystalline vs. Amorphous State

Oral dosage forms are the preferred dosage form throughout most of world based on
ease of administration and bulk manufacturing advantages.

These can take many

different forms such as capsules, liquids, liquid-filled capsules, orally dissolving strips,
but the most common and cost-effective form is a tablet. The ability to provide a stable,
consistent, regulatory compliant, and effective drug product is vital to pharmaceutical
industry and oral solid dosage forms currently offer the best solution for the majority of
compounds.11
Solids can exist in multiple different states. The first, and most well recognized, is
the crystalline solid which has a defined long-range order and molecular packing.
However, solids can also be amorphous in nature. These amorphous solids have no longrange order, but possess the physical characteristics of a solid (such as a defined volume
and little-to-no flow). The ability to understand and utilize different solid forms is
necessary to optimize solid oral dosage forms. The following section outlines the major
properties of crystalline and amorphous solids and summarizes the thermodynamic
differences.

1.2.1

Crystalline Systems

Crystalline solids are the backbone of solid dosage forms and are usually
considered the starting point for formulation development. They possess very specific
physical and chemical properties which can be utilized and manipulated in order to
achieve the desired formulation effect. Understanding the properties of crystalline solids
is the first step in understanding how to formulate solid dosage forms.
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The four basic forms of matter, solid, liquid, gas, and plasma, all have unique
properties which define them. Solids are simply defined as structurally rigid and resistant
to change of shape or volume. Within the solid classification, solids can further be
differentiated into crystalline or amorphous solids (which will be discussed momentarily).
Crystalline solids exhibit a molecular ordering or long-range order which has a specific
periodicity of the molecules.

Essentially, the molecules of a given substance in a

crystalline solid arrange themselves in a regular, repeating fashion so that they have
favorable interactions with other molecules within the crystalline solid.

These

intermolecular interactions are either in the form of hydrogen bonds or other noncovalent bonds (such as van der Waals forces or electrostatic interactions).

The

formation of this regular periodicity through the creation of these bonds significantly
lowers the internal free energy of the crystal.

Therefore, crystalline solids have a

multitude of distinguishable properties which we can observe and subsequently try to
manipulate.
The chemical structure of a molecule directly dictates this periodic arrangement,
specifically the polarity, symmetry, and functional groups of the molecule greatly impact
the ability of the molecules to pack in an efficient manner. The ability of a molecule to
arrange itself in an ordered fashion leads to a specific molecular packing and crystal
density and gives rise to the concepts of the unit cell, point and space groups, crystal
shape, habit, and morphology. The unit cell of a crystal lattice is the smallest unique
arrangement of molecules (illustrated in Figure 1-1) while the point and space groups are
built off of how these unit cells are arranged together. The macroscopic crystal features
such as shape, habit and morphology are determined by a combination of the unit cell,
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point and space group symmetry along with the growth rates of particular facets of these
microscopic crystal features.

Furthermore the chemical structure and subsequent

intermolecular interactions and packing determine key physical properties including the
melting temperature, heat capacity, and solubility. The unit cell is the building block for
the crystal structure and understanding how a given compound interacts in the crystal is
key for understanding its physicochemical properties.
The lowered free energy of the crystal, achieved through stabilizing molecules in a
uniform arrangement, sets crystalline materials apart from their liquid, gas, and even
amorphous solid counterparts in terms of their properties. Typically, at room temperature,
crystalline solids are the most thermodynamically stable phase and are thus the preferred
form for formulations since phase transformations are not thermodynamically favored.
However, the same lower internal free energy that leads to better solid state and chemical
stability can also yield issues with dissolution and solubility because the most
thermodynamically stable form is also the least soluble. This topic will be discussed in
detail later.
In contrast to the internal free energy, the surface energy of a crystalline solid is
higher. The lattice bond structure required for crystalline solids creates an interface
which will have unfavorable molecular interactions with the surrounding phase. The high
surface energy of crystalline solids provides a barrier to crystallization and the
thermodynamics of the crystallization process are complex. Figure 1-2 graphical displays
the competing processes of surface free energy and internal (volume) free energy and the
overall effect on the total free energy of a system.

Nucleation and crystal growth
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mechanisms have been explored extensively and play crucial roles in dictating the
properties of resultant crystalline solids.12, 13
In addition, a single compound can exist in several different crystal forms, each
with their own properties, which can be either advantageous or detrimental to the
formulation process depending on their properties. Polymorphs arise when the molecule
can pack into different arrangements in the crystal lattice leading to different unit cells,
internal free energy and other properties. The thermodynamic relationship between
polymorphs, which underlies the differences in properties, can be characterized by phase
diagrams as shown in Figure 1-3.
Polymorphs can be classified as either enantiotropic or monotropic.

In

enantiotropic systems, the most stable polymorph varies with temperature below the
melting point (Crystal A and B in Figure 1-3) leading to a transition temperature.
Polymorphs are considered monotropic when there is one polymorph that is the most
stable through the entire temperature range up to the melting point (Crystals A and
C/Crystals B and C in Figure 1-3).14
Alternatively, a compound can have many other crystalline solid forms such as
hydrates (water is incorporated into the crystal lattice), solvates (solvent is incorporated
into the crystal lattice), salts (ionized, with a counterion present in the lattice), and cocrystals (two different neutral compounds in the same crystal lattice). These forms will
not be discussed further since they are outside of the scope of this research.15
All of these crystalline forms have distinct properties dictated by the way in which
the molecules arrange and interact with each other within the crystal lattice. These
interactions create the crystal lattice energy which directly affects properties such as
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solid-form stability, melting temperature, and solubility. The solubility, or ability for one
substance to dissolve and form a homogeneous mixture within another substance, is
vaguely defined throughout literature and can sometimes be confusing with terms such as
“apparent” solubility, “intrinsic” solubility, and “equilibrium” solubility in widespread
use.1, 3, 5, 6 The following terms and definitions will be used herein:


Solubility – this refers to crystalline solubility of the most thermodynamically
stable form of a substance and is achieved by reaching an equilibrium between the
crystalline material and the solution phase; it is dependent on the solution phase
and temperature, both of which must be specified. This is also sometimes defined
as intrinsic solubility or equilibrium solubility.



Amorphous Solubility – the amorphous solubility is the maximum concentration
achievable through the dissolution of the amorphous form of a drug with the
formation of a temporary equilibrium between the solvent and the amorphous
material. Any equilibrium achieved is only temporary because the system is
supersaturated with respect to the crystalline solubility and at some point
crystallization will occur; thus this is a metastable equilibrium. This will be
discussed further in the following sections.

1.2.2

Amorphous Systems

Amorphous solids are thermodynamically metastable compared to the crystalline
complement.

They have short–range intermolecular interactions such as hydrogen

bonding and other non-covalent forces but lack the long range order and periodicity
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found in crystalline solids. Amorphous solids below the glass transition temperature
have a rigid physical structure but lack the basic molecular packing which could define a
point/space group, habit, or shape.
Amorphous materials can be delineated as super-cooled liquids and glasses which
are separated by the glass transition temperature (Tg). Above the Tg, the material is a
supercooled liquid which has a high molecular mobility and a heat capacity that is
continuous with the heat capacity of the equilibrium liquid, however supercooled liquids
occur below the melting temperature of the compound and are thus metastable relative to
the crystal. Glasses are amorphous solids below the Tg, have a lower molecular mobility
as well as a lower heat capacity as compared to the supercooled liquid. These trends are
summarized in Figure 1-5.
Amorphous solids have a higher free energy than the crystalline form and
consequently are metastable relative to the crystalline form. These properties can be
taken advantage of for oral drug delivery, as the higher energy can lead to increased
dissolution/solubility and subsequently higher bioavailability.

However, amorphous

solids are more chemically reactive16 and tend to crystallize into the more stable form
which creates issues with solid oral dosage formulation stability. The use of additives to
inhibit crystallization from both the solid dosage form and the aqueous dissolution
medium (i.e. GI tract) is common.2, 3, 5 Zografi et al. elegantly described the two major
competing forces which impact the crystallization of amorphous solids; the large
thermodynamic driving force for nucleation which favors crystallization and the low
molecular mobility which provides a kinetic barrier to crystallization.

Figure 1-6

diagrams these effects. As can be seen from the figure, the driving force for nucleation is
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increased with the decrease in temperature below the melting point. In contrast, the
molecular mobility decreases as the system approaches the glass transition, which hinders
the molecular rearrangement needed to form ordered crystals. A maximum rate between
the melting temperature and the glass transition temperature is reached where the
thermodynamics of nucleation and the kinetics of molecular mobility are optimal for
crystallization from the amorphous material.4
Amorphous solids have been shown to provide greater bioavailability than many if
not all other types of solubility enhancement.2, 3, 5, 17, 18 As a result, understanding the
thermodynamic and physical properties associated with all aspects of an amorphous
dosage form is critical to formulating efficacious products. The amorphous solubility, as
defined earlier, is the term given to the solution concentration that can be achieved
through the dissolution of the amorphous form of a substance. Because of the higher
energy state and more disordered structure of an amorphous solid, there are fewer bonds
between molecules to be broken and this leads to more facile dissolution as compared to
the crystalline form. Within a solution, this creates a concentration that is higher than the
crystalline solubility, leading to supersaturation and ultimately is a metastable system.
There are many different processes that can occur during the dissolution of an oral dosage
form and Figure 1-7 outlines these competing processes.
The thermodynamics and kinetics of the various phase transformationswill
determine the overall stability of the system. This will be discussed in detail in the
thermodynamic section below but the important detail that is rarely considered is that the
amorphous solubility is a second boundary within the phase diagram, above which a
driving force for an additional phase transition (liquid-liquid phase separation) is present.
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1.2.3

Amorphous Solid Dispersions

Although amorphous solids have been shown to provide improvements in the
apparent solubility they are not sufficiently stable to use without excipients that can
prevent crystallization in the solid formulation. Polymers are thus frequently blended
with the amorphous drug to create an amorphous solid dispersion (ASD), providing a
formulation approach whereby the amorphous form of a drug can be stabilized and the
resultant solubility benefits utilized to improve bioavailability.19, 20 The polymers act to
preserve the amorphous form of the drug. There are many ways to create amorphous
solid dispersions, and ideally a homogeneous molecular level dispersion results from the
manufacturing process since this will provide maximum stability against crystallization.
Melt extrusion, spray drying, and co-precipitation have been used to effectively make
solid dispersions with good stability against crystallization.21, 22
A schematic of an amorphous molecular level dispersion is shown in Fig. 1-7. Here
it can be seen that the drug molecules are uniformly dispersed in the polymer matrix.
Because of the molecular level mixing in the drug dispersion, the polymer is in intimate
contact with the drug and therefore has a major impact on the crystallization behavior.
Mechanistically, the stabilizing effect of polymer has been attributed to a number of
factors. The polymer molecules increase the viscosity of the solid, decreasing molecular
mobility and hindering crystallization. The polymer molecules can also act as a physical
barrier between drug molecules, reducing the tendency for the self-assembly needed for
crystallization. Additionally, the polymer can interact with the drug through hydrogen
bonding or van der Waals forces, effectively reducing the ability of the drug molecules to
diffuse to the crystal. The effectiveness of a polymer as a crystallization inhibitor is
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highly dependent on the extent of miscibility between the drug and polymer.23, 24 ASDs
are considered the main approach for formulating amorphous solids and are currently the
subject of intense research effort.

1.3

Thermodynamics and Kinetics

The phase transitions within crystalline and amorphous systems depend on both
thermodynamics and kinetic factors. Thermodynamics account for whether or not a
phase change or transition can occur based on the excess energy within the system. The
kinetics, dictate whether or not a change or transition will be observed over a given time
frame. The following section will highlight the contributions of both and provide a
foundation for understanding the driving forces behind the phenomena under
investigation in this research.

1.3.1 Free Energy Diagram
Phase transitions result in changes in the thermodynamics of the system and
proceed from a higher energy to a lower energy state. Gibbs derived the elegant Gibbs
free energy (∆𝐺) equation which shows the interplay between two important parameters:
∆𝐺 = ∆𝐻 − 𝑇∆𝑆
Equation 1-1
The equation shows the balance between two terms; the change in enthalpy (∆𝐻)
and change in entropy multiplied by temperature (𝑇∆𝑆). The enthalpic component
represents the energy change of the system, such as when intermolecular bonds are
broken leading to an increase in energy. The entropic term affects the free energy
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through the changes in the extent of disorder in the system. Again using the breaking of a
bond as a reference, the entropy of the molecule will increase due to the increased
freedom of movement due to the lack of a bond (rotational, translational, or
configurational freedom) and the entropy term is directly related to the temperature of the
system. The overall free energy of a system as shown by Equation 1-1 is a balance
between the changes in enthalpy and entropy. Due to the contribution of temperature to
the entropy term, there will come a point where the entropy of the system will dominate
the overall free energy of the system. As we decrease the temperature, we see that the
enthalpic term will become more prevalent and the underlying energy associated with
bond formation and interfaces play a large role in dictating the overall free energy of the
system.15
Figure 1-9 illustrates the excess enthalpy (or volume) as a function of temperature
for an amorphous material relative to the crystal. Thermodynamically, the temperature at
which the entropy contribution of the system overtakes the enthalpy contribution is
known as the fusion point (or melting point, Tm). This change between enthalpy and
entropy dominance is accompanied by a phase transition from the crystal to the liquid.
Amorphous systems arise when the system temperature is lowered below the fusion point,
usually through rapid cooling, without an accompanying structural change into the crystal.
The supercooled liquid has the structural characteristics of a liquid but with a much
greater viscosity and is thermodynamically metastable relative to the lower free energy
crystal. A second transition which is kinetic in origin occurs where the molecular
mobility within the liquid decreases greatly, resulting in a "kinetically frozen" material
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and another change in the enthalpy/temperature relationship.4 This temperature is known
as the glass transition temperature (Tg).
The stability of a phase is dictated by the balance of the enthalpy (energy) and
entropy (order) of the substance. If the system is thermodynamically metastable or
unstable, then there are one or more phases that exist with a lower free energy under the
same conditions of temperature and pressure, and the phase transition will be dictated by
kinetic factors. Within amorphous systems, properties such as dissolution and diffusion
of molecules which impact crystallization are kinetically controlled.
For multicomponent systems, which can be as simple as the amorphous or
crystalline system in contact with the solvent, it is critical to understand the
thermodynamics of mixing two phases.

1.3.2

Mixing Energy and Solubility

When considering the solubilization of a crystal versus the corresponding
amorphous solid, the different thermodynamic properties of the two forms needs to be
considered. Figure 1-10 is a diagram that depicts the processes needed to solubilize a
crystalline solid. The first step in solubilization is the breaking of the crystal lattice
bonds. One way of describing this thermodynamically is through a heat and cool cycle.
Energy must be supplied to heat the crystalline solid to the melting point and additional
energy must be added to break the bonds within the lattice to form a liquid; this is the
enthalpy of fusion (∆𝐻𝑓 ). Once the bonds are broken, the solid is now a liquid and must
be cooled down, with release of energy, and then the pure liquid form of the compound is
mixed with the solvent to form a solution. The free energy change can be written as:
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∆𝐺𝑠𝑜𝑙𝑛 = ∆𝐻𝑠𝑜𝑙𝑛 − 𝑇∆𝑆𝑠𝑜𝑙𝑛
Equation 1-2
As can be seen from Figure 1-10, the ∆𝐻𝑠𝑜𝑙𝑛 term consists of two individual
enthalpy terms, the heat of fusion, ∆𝐻𝑓 , necessary to break the lattice bonds, and the heat
of mixing, ∆𝐻𝑚𝑖𝑥 , which reflects the balance between the new interactions formed
between the solute and solvent molecules and these interactions in each of the pure
components. Assuming the molecules are similar in size and polarity, we can assume an
ideal solution; i.e. the bonds broken in each individual liquid phase are equal to the bonds
formed in the new homogeneous phase and thus there is no energy change, ∆𝐻𝑚𝑖𝑥 = 0.
Therefore, ∆𝐻𝑓 = ∆𝐻𝑠𝑜𝑙𝑛 . In other words, for an ideal solution, the solubility is only
dictated by the properties of the crystal. Since the heat of fusion is easily determined from
melting data, estimates of the crystal contribution to solubility can readily be made, as
will be discussed in more detail below.
The entropy of the solution is more complex. Again, assuming an ideal solution,
the entropy of solution can be calculated25 as follows:
∆𝑆𝑠𝑜𝑙𝑛 = ∆𝑆𝑚𝑖𝑥 = −𝑅( 𝑥𝐴 ln 𝑥𝐴 + 𝑥𝐵 ln 𝑥𝐵 )
Equation 1-3
The entropy of mixing thus depends on the mole fraction of each component
(𝑥𝐴 , 𝑥𝐵 ) multiplied by the gas constant (R).

In an ideal solution, the two different

molecules are similar in both chemistry and size, and the entropy of mixing can be
readily estimated. While polymers and water are an example of non-ideal mixing, the
assumption of an ideal entropy of mixing may be reasonable for drugs mixing with water.
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Further derivation with the approximations described in 26 enables us to describe the
free energy change for forming a solution as:
∆𝐺𝑠𝑜𝑙𝑛 = −𝑅𝑇 ln 𝑥𝑠𝑜𝑙𝑢𝑡𝑒 = ∆𝐻𝑓 − 𝑇∆𝑆𝑓
Equation 1-4
With the assumption of ideality, the entropy of fusion ∆𝑆𝑓 can be derived from the
melting temperature and enthalpy of fusion, ∆𝐻𝑓 /𝑇𝑀 . Because the entropy and enthalpy
values are dependent on temperature, and the systems being evaluated are usually at
much lower temperatures, the heat capacity difference (Δ𝑐𝑝 ) between the liquid and the
crystal is needed to determine the entropy and enthalpy at the temperature of interest.
Simplifying and rearranging the equation to express it in terms of the mole fraction
solubility of the solute yields:
ln 𝑥𝑠𝑜𝑙𝑢𝑡𝑒 =

−∆𝐻𝑓 1
∆𝑐𝑝
1
𝑇𝑚
𝑇𝑚
( − )−
(1 −
+ ln )
𝑅
𝑇 𝑇𝑚
𝑅
𝑇
𝑇
Equation 1-5

Equation 1-5 is a fairly accurate representation of the energy needed to incorporate
a molecule into an ideal solution from a crystalline solid. However, the use of this
equation to predict solubility involves the assumption that the solute and solvent
molecules are very similar in structure and interactions. The drugs of interest for this
research are hydrophobic, complex molecules which violate this assumption. Therefore,
the activity coefficient (𝛾) term is added in order to account for differences in interactions
between each pure phase and the mixed phase. The activity coefficient describes the
deviation of the system from ideality and where 𝛾𝑥 yields the activity of a molecule (𝑎), a
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dimensionless factor directly related to the chemical potential of the molecule. Adding in
the activity coefficient term leads to equation 1-6:

ln 𝑥𝑠𝑜𝑙𝑢𝑡𝑒 = [

−∆𝐻𝑓 1
∆𝑐𝑝
1
𝑇𝑚
𝑇𝑚
( − )−
(1 −
+ ln )] − ln 𝛾
𝑅
𝑇 𝑇𝑚
𝑅
𝑇
𝑇
Equation 1-6

Understanding all of these factors that contribute to the behavior of a drug in
solution reveals the intrinsic relationship between the solubility (represented here as the
solute mole fraction) and physical properties of the molecule.

Experimentally

determining the crystalline solubility and comparing this value to the estimated ideal
solubility enables the magnitude of the activity coefficient to be determined. Thus it is
possible to understand the underlying cause of poor solubility of a given crystalline
compound, namely if the main contribution is from a large lattice energy, or due to the
hydrophobicity of the molecule which leads to a large activity coefficient. For most
compounds, a combination of both of these factors leads to poor aqueous solubility. For
compounds where the lattice contribution has a substantially negative impact on
solubility, using an amorphous formulation is theoretically beneficial as a solubility
enhancement strategy.

1.3.3

The Amorphous Solubility Advantage

The previous section outlined the relationship between the free energy of a
solution and the solubility of a crystalline solid as well as its relationship to the activity of
a molecule. This relationship can be used to estimate the amorphous solubility advantage.
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To estimate this, it is necessary to approximate the free energy difference between the
crystalline and amorphous forms; this can be done using the Hoffman equation27:
∆𝐺𝑐→𝑎 = (

∆𝐻𝑓 × ∆𝑇 𝑇
)( )
𝑇𝑚
𝑇𝑚

Equation 1-7
While, equation 1-7 is a good approximation of the free energy difference
between crystalline and amorphous forms, accounting for the changes in enthalpy and
entropy with respect to temperature, one major assumption should be noted:

The

derivation by Hoffman assumes that the temperature range of the system will be between
𝑇𝑚 and 𝑇𝑔 .

However, relevant temperature ranges for conducting pharmaceutically

relevant research usually fall below the 𝑇𝑔 of a drug. Additionally, it is assumed that the
heat capacity has a linear relationship with temperature and the difference in heat
capacity between the solid and liquid states is constant; this has been shown to be a
reasonable assumption over small temperature ranges.5 The ratio of the mole fraction
solubility of the amorphous form (𝜎𝑎 ) and the crystalline form (𝜎𝑐 ) can also be related to
the free energy difference as follows:
∆𝐺𝑐→𝑎 = 𝑅𝑇 ln

𝜎𝑎
𝜎𝑐

Equation 1-8
Combining these two equations leads to:
𝜎𝑎
=𝑒
𝜎𝑐

∆𝐻𝑓 ×∆𝑇 𝑇
(
)( )
𝑇𝑚
𝑇𝑚
𝑅𝑇

Equation 1-9
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If the crystal solubility, the melting temperature and the enthalpy of fusion are
known, then equation 1-9 provides a means to estimate the amorphous solubility.
Equation 1-9 has been found to provide reasonable estimates of the amorphous solubility
for a number of compounds28, and is expected to work well for compounds with Tg
values close to the experimental temperature and with a very low capacity to absorb
water. However, most amorphous solids absorb significant amounts of water (on a molar
basis) and a correction to the solubility estimate is needed to take into account the water
mixed with the amorphous solid. Murdande outlined an additional term to account for
the water in the amorphous solid. This correction factor can be estimated from the
moisture sorption profile of the amorphous form of the drug. Thus [−𝐼(𝑎2 )] is the
activity of the amorphous solid saturated with water and equation 1-9 is modified to5:

𝜎𝑎 = 𝜎𝑐 × 𝑒[−𝐼(𝑎2 )] ×

∆𝐻𝑓 ×∆𝑇 𝑇
(
)( )
𝑇𝑚
𝑇𝑚
𝑅𝑇
𝑒

Equation 1-10
Murdande went on to show that adding the water sorption correction is important
for estimating the amorphous solubility in some organic molecules.5, 17, 18 One major
problem with the experimental assessment of amorphous solubility is that crystallization
tends to occur before equilibrium with the amorphous solid is reached.6 Adding polymers
may delay crystallization so that a better experimental value can be obtained.28,

29

However, it is consistently observed that dissolution of amorphous solid dispersions
creates solutions that are supersaturated with respect to the crystalline solubility.28, 30

19
1.3.4

Supersaturation

In practice, supersaturation (𝑆) is usually expressed as the ratio of the solution
concentration (𝑐) to the crystalline (or equilibrium) solubility concentration (𝑐 ∗ or 𝜎𝑐 ).
𝑆=

𝑐
𝑐∗

Equation 1-11
Supersaturation can be defined on a more rigorous thermodynamic basis using the
chemical potential of a molecule in an equilibrium state (𝜇𝑒𝑞 ) and in a supersaturated
state (𝜇𝑠𝑠 ). The chemical potentials of two components in equilibrium are equal to one
another. The chemical potential of a supersaturated solution can be defined as:
𝜇𝑠𝑠 = 𝜇𝑒𝑞 + 𝑅𝑇 ln 𝑎𝑖
Equation 1-12
Where a is the activity of the solute in the solution. The activity is the product of
𝑐

the activity coefficient of a molecule and the excess molecules, 𝑐 ∗ , or supersaturation.
Thus, when the concentration of a solution is above the crystalline solubility,
supersaturation is above 1, leading to an increase in solute chemical potential. The
increase in solute chemical potential creates a thermodynamic driving force for phase
transitions to occur. Figure 1-11 below summarizes the phase behavior of a system.
The diagram depicts 3 distinct regions (I, II, and III). Region I is a stable regin,
being an undersaturated, homogenous solution; the concentration is not high enough for
any phase change to occur at a given temperature. In this region, the supersaturation ratio
is less than 1 (i.e. the solution is undersaturated) and therefore the solution is stable and
addition of crystalline material will lead to dissolution. Region II depicts a region above
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the crystalline solubility but below the amorphous solubility as defined earlier. The blue
solid line represents 𝑐 ∗ otherwise known as the crystalline solubility or equilibrium
solubility.

All concentrations above this line at a given temperature have a

supersaturation ratio greater than 1, and have a thermodynamically driving force for
crystallization. The dashed blue line defines a metastable crystallization zone (II-m) in
which crystallization can occur through secondary nucleation.31 Below this line, crystals
can grow if seeds are added, and secondary nucleation (discussed later) is also possible.
Above this line primary nucleation can spontaneously occur. The last region, III, is above
the amorphous solubility and is a region where liquid-liquid phase separation can occur
(thought of as amorphous precipitation) and crystallization can also occur. Again, the
dashed red line defines a meta-stable zone (III-m) of LLPS where an energy barrier needs
to be overcome (again discussed later).
Overall, the diagram shows two major solubility curves, the crystal solubility and
the amorphous solubility with thermodynamic driving forces existing to cause
precipitation (defined here as the formation of a new phase) either through crystallization
or LLPS. Furthermore, above the amorphous solubility, the two phase transformations
(i.e. LLPS and crystallization) will compete and the observed phase will be determined
by the relative transformation kinetics of each process at a given concentration and
temperature.

1.3.5

Kinetics

The thermodynamics of the system explains whether or not a phase transition is
possible through defining the energy gradient of a system. The rate of transformation to
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the new phase, which may or may not be the lowest free energy phase depends on the
kinetics of the system.
Within a solution, the kinetics are the rates at which the reactions between
molecules leading to a phase transformation occur, and is impacted by factors such as
temperature, mass transport and conformational differences. Focusing on the kinetics of
the molecules forming or decaying from a specific phase allows us to obtain a complete
picture of phase transformations.

The dissolution of one phase into another (most

commonly a crystal into a liquid) along with the diffusion of molecules within a single
phase will briefly be discussed in this section.

1.3.5.1 Dissolution
The kinetics of dissolution determine the rate at which one phase dissolves in
another phase, and becomes one homogeneous phase. This process is most commonly
researched as the dissolution of solids into liquids. The kinetic process of removing a
molecule from one phase and incorporating it into another requires multiple processes to
occur in succession; the bonds within the solid phase must be broken followed by the
incorporation into the new phase. Many factors contribute to the rate of dissolution
including both physical and chemical properties.
There are many models which attempt to predict the dissolution behavior of given
systems. Zero, first, and second order models are simplistic mathematical models that
account for number of species involved while further derivations begin to apply
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mechanistic and chemical parameters, such as Hixson-Crowell, Higuchi, and the Weibull
models.
These models have been used to predict the dissolution of crystalline and
amorphous solids into aqueous media.

In more recent research, the dissolution of

amorphous solid dispersions has been investigated.

Characterizing the dissolution

profiles of ASDs is one of the most relevant topics of research regarding amorphous
drugs based on the potential to increase drug concentrations. Figure 1-12 shows that the
dissolution of the pure amorphous solid can yield higher solution concentrations than the
crystalline counterpart. As can be seen from the figure, the dissolution profiles differ
drastically depending on the solid state properties.
Polymers are widely used in ASDs in order to prevent crystallization in both the
solid matrix and within solution once dissolved. The use of polymers for inhibition of
crystallization has led to the “spring and parachute” concept of dissolution profiles.
Figure 1-13 demonstrates the difference between this type of dissolution profile and the
dissolution of the stable crystalline form.
All of the research thus far into the dissolution of amorphous solids and more
importantly ASDs has sought to model, predict, observe, and analyze the solution
concentration of the drug. The logic is that the higher the sustained drug concentration,
the more solubilized drug can be absorbed by the body (either passively or actively).
However, beyond considering the crystallization of the drug, none of the research
typically conducted seeks to incorporate the consequences of creating such highly
supersaturated drug solutions into the phase behavior of these systems. The following
sections will outline the factors affecting both crystallization and the formation of a
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second liquid phase (LLPS) within these systems.

Achieving a more complete

characterization of highly supersaturated systems should be incorporated into the current
understanding of dissolution behavior in order to better understand the effect on the drug
concentration and ultimately the bioavailability of the drug.

1.3.5.2 Diffusion
The second major kinetic process is the diffusion of the molecules within a given
phase. While this topic is somewhat out of scope of the current research, a basic
understanding is required to fully grasp the concepts of phase behavior within solutions.
Diffusion is the motion of the particles within the system. This process will be
strongly influenced by environmental parameters such as temperature, pressure, and
intermolecular interactions. Simplistically we can use Fick’s first law of diffusion to
describe the motion of molecules within a given phase.
𝐽=−

𝐷𝑐𝑖 𝜕𝜇𝑖
𝑅𝑇 𝜕𝑥

Equation 1-13
Here, 𝐽 is the diffusion flux or amount of material that will move through a certain
area during a certain time period. 𝐷 is the diffusion coefficient, 𝑐𝑖 is concentration, 𝜇 is
the chemical potential, 𝑅 is the universal gas constant, 𝑇 is temperature, and 𝑥 is the
position. As can be seen from the equation, the diffusion of a molecule depends on the
temperature, concentration, chemical potential, and diffusion coefficient; all of which
vary from substance to substance. Additionally, the diffusion coefficient is derived from
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the Stokes-Einstein relationship and depends on the contributions of temperature,
viscosity, and size of the molecule.
All of these factors can affect the diffusion rate of molecules within a system,
ultimately leading to effects on phase transformations. For example, if the concentration
is increased, the flux increases and thus more molecules can move in a certain area
leading to more collisions and a lower energy barrier to phase transitions. The following
sections will outline these phase transitions.

1.4

Crystallization

Crystallization is the process of creating a new crystalline solid phase and can be
divided into two processes, nucleation and crystal growth.

For crystallization from

solution to occur, the chemical potential of the solute in solution must be greater than that
of the solid, i.e. the solution is supersaturated. Once an energy barrier is overcome, the
solute molecules will nucleate and subsequently undergo crystal growth until the system
has reached equilibrium, i.e. the chemical potential of the solute in the solution is equal to
that of the crystal.
When designing formulations that create a supersaturated solution of a drug, both
processes must be considered in order to understand the longevity of the supersaturation
that is generated following dissolution. Different mechanisms are important for crystal
growth and nucleation and understanding each process independently will aid in
comprehending the crystallization process as a whole.

Solubility enhancement

techniques purposefully create concentrations higher than the equilibrium solubility in
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order to increase the bioavailability of the drug. Thus, nucleation and crystal growth are
issues that must be dealt with by formulators.

1.4.1

Nucleation

The initial event of creating a new crystalline solid phase from another phase is
called nucleation. Nucleation is a first-order phase transition where the rate at which
nucleation occurs is determined by the concentration of a single entity, in this case the
drug.12, 13, 32 Other factors such as excipients33 and pH9 can affect the nucleation rate,
albeit indirectly through altering the effective concentration of the drug molecule. The
first nucleus of a given species within a given species is referred as primary nucleation.
Any nuclei that result from a system with nuclei already present are referred to as
occurring by secondary nucleation. Furthermore, nucleation can occur through one of
two major mechanisms;
1) Homogeneous Nucleation – nuclei that occur within the interior of a single,
homogeneous phase with no external seeding or catalysts. While this model is
extensively used,12, 27, 34 this type of nucleation is exceedingly rare to observe
experimentally because of impurities in most real systems. All homogeneous
nucleation is primary nucleation.
2) Heterogeneous Nucleation – nuclei that form at preferential sites within a
system such as phase boundaries, cell/beaker walls, existing crystals, or other
entities which are not a part of the homogeneous phase.

Heterogeneous

nucleation can be considered both primary and secondary nucleation.
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In general, these two types of nucleation mechanisms have different energy barriers
with primary homogeneous nucleation having the highest energy barrier for a given
system. Within the scope of this research, the broad term of nucleation will be used to
describe experimentally observed processes which may encompass both homogeneous
and heterogeneous nucleation unless otherwise stated. This section will outline some of
the theories of nucleation and why each theory is relevant to the overall goals of this
research.

1.4.1.1 Classical Nucleation Theory
The first nucleation theory was derived by Gibbs and describes the homogeneous
nucleation of droplets from a vapor.35, 36 Classical nucleation theory (CNT) is a statistical
approach based on the sequential addition of single molecules to a cluster until a critical
size is reached. The critical size is determined from the balance of the unfavorable
energy of creating a new phase (increase in free energy of the system) and the favorable
energy resulting from intermolecular bond creation during formation of a crystal lattice
(decrease in free energy of the system). Considering a solid nucleus rather than a liquid
droplet, we can model the Gibbs free energy of a new nucleus of size, 𝑛. As stated, there
are two major competing effects for the formation of a new nucleus. The first is the
unfavorable contribution from creating a new phase boundary with an area, 𝑆, described
by the surface free energy between the nucleus and the solution, 𝛼. A shape factor is
added to described the geometry of the nucleus (such as 6𝑎2 for a cube with side length
of 𝑎) and this will lead to a gain in free energy. On the other hand, there is a negative
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free energy contribution due to the chemical potential of a molecule in the solid being
lower than that of a molecule in a supersaturated solution, ∆𝜇 = 𝜇𝑠𝑜𝑙𝑢𝑡𝑒 − 𝜇𝑐𝑟𝑦𝑠𝑡𝑎𝑙 > 0.
Therefore the overall contribution of free energy of a nucleus of size n to a system is
−𝑛∆𝜇. The overall Gibbs free energy equation for the formation of a nucleus is:
∆𝐺(𝑛) = −𝑛∆𝜇 + 𝑆𝛼
Equation 1-14
This dependence is outlined in the Fig. 1-15; a critical nucleus size is reached once
the energy associated with lowering the potential of the molecules due to forming a
crystal lattice outweighs the energy associated with creating a new interface. The critical
nucleus size can be determined for a given system and marks the energy barrier that must
be exceeded for nucleation to occur. This model has been studied both theoretically and
experimentally as well as modified to consider many different assumptions but the basic
assumption is that nucleation is a stochastic event. The model requires the right number
of molecules to associate together to begin to form a crystal lattice the timeframe for
which will depend on the kinetics of the system. If the cluster of these molecules is large
enough (≥ 𝑛∗ ) then the cluster can survive and continue to grow. If the cluster is not
large enough (≤ 𝑛∗ ) then the molecules are driven to decay and the subcritial nucleus
dissolves. The critical nucleus size is defined as the point at which a cluster of a given
size can either become a viable nucleus or decay back into solution.12
CNT led to the derivation of a crystal nucleation rate equation, by Volmer who
proposed an equation for the rate of nucleation, (𝐽), based on the Arrehenius equation,
∆𝐺 ∗

𝐽 = 𝐽0 exp(− 𝑘 𝑇), where 𝑘𝐵 is the Boltsmann constant, 𝑇 is temperature, and ∆𝐺 ∗ is the
𝐵
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critical free energy change necessary to form a stable nuclei. ∆𝐺 ∗ , as can be seen in
Figure 1-15, is to the thermodynamic barrier to nucleation with the nucleation rate also
depending on: temperature, supersaturation (chemical potential difference, which impacts
the magnitude of ∆𝐺 ∗ ), and pressure. The most common adaption of the original Volmer
equation is:
𝐽 = 𝑣 ∗ 𝑍𝑛 exp(−

∆𝐺 ∗
)
𝑘𝐵 𝑇

Equation 1-15
The final expression includes a term for the rate of attachment (𝑣 ∗ ) of monomers
(𝑛) and the Zeldovich factor (𝑍). Many assumptions are made to derive this equation,
most of which depend on mass balance and degrees of freedom within the system, but the
most important one to consider is that the model assumes that solution molecules are
exchanged directly with an ordered cluster or nucleus.
Overall, the CNT with one energy barrier to overcome to achieve nucleation has
been revised

13, 32, 34, 37

to include additional factors and in some instances can predict

nucleation in specific systems, whereas in other systems, large discrepancies between
experiments and predictions are observed.10, 34 Such discrepancies have led to a proposal
for a different mechanism for nucleation.

1.4.1.2 Two-Step Nucleation
The assumption that molecules may directly exchange with the ordered cluster
has been called into question based on what we know about ordered processes and other
thermodynamic transitions. The basic principle behind forming an ordered cluster or

29
nucleus relies on the molecules of solution undergoing a transition in not one but two
order parameters; concentration and structure.

For example, assume we have an

amorphous solid, which is unstable and will have a driving force to crystallize. The local
concentration of the molecules will not change drastically as the molecules are seemingly
just rearranging themselves within the solid to form an ordered crystal lattice. However,
in order to form a crystal from solution, molecules must first condense to increase their
local concentration and subsequently increase their structural order.

Figure 1-16(a)

shows this phenomenon as it pertains to solution crystallization. CNT refers to the
diagonal line from the top left, solution phase, to the bottom right, nucleus phase. Twostep nucleation theory proposes that two processes must occur in order to form a nucleus
each with their order energy barrier; the first being to increase the concentration through
the creation of a dense liquid phase, and the second being the rearrangement of order to
form an ordered cluster from the dense liquid. Figure 1-16(c) is a diagram of these energy
barriers, demonstrating two types of two-step nucleation. The first (top) creates a denseliquid phase which is metastable relative to both the solution and crystal phase. The
instability of the dense-liquid phase forces the molecules to rapidly proceed into the
ordered cluster state, or decay back into solution. The second (bottom) shows a scenario
where the dense-liquid phase is more stable than the solution phase and thus more likely
to be observed. The presence of a dense-liquid (or amorphous) phase may be attributed
to high supersaturation, high immiscibility with the solvent, combined with slow
crystallization/dissolution kinetics.38
The presence of a dense-liquid phase has been observed to occur with proteins such
as lysozyme 39 and has been more recently observed in other proteins,40 and small organic
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molecules.41 The agreement of experimental data on nucleation rates with differing
nucleation theories is highly variable. Some data supports the CNT in certain regimes
(such as low supersaturation or simple systems such as NaCl). Other experimental
nucleation rate data is considerably underestimated by the CNT and shows evidence of a
second dense-liquid phase before crystallization.38
Although fundamental nucleation mechanisms are still under debate, they provide a
framework for understanding how the nucleation process can be manipulated through the
use of additives, which is essential when using supersaturating dosage forms.

1.4.2

Crystal Growth

Once nucleation has occurred, the growth of crystals dominates the system. In
highly supersaturated systems, such as those created from the dissolution of amorphous
solid dispersions, nucleation becomes the rate limiting step in crystallization, so long as
there are not any excipients added to the system to specifically inhibit crystal growth.
This section will provide a very broad, overview of crystal growth as it is important to the
overall understanding of this research.
Crystal growth rate is dictated by two main processes. The first is the rate of
diffusion of molecules through the solution to the crystal surface and the second is the
rate of integration of these molecules into the crystal lattice. The crystal growth rate
therefore becomes the summation of the two processes. Derivations have been made to
theoretically calculate these rates and there are a few major parameters that need to be
considered.

Concentration both in solution (diffusion) and around the crystal face

(integration) need to be accounted for as well as the temperature of the system.
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𝑅𝐺 = 𝑘𝐺 (𝐶∞ − 𝐶 ∗ ) 𝑔
Equation 1-16
Equation 1-16 is a simplified growth rate equation depicting the mass growth of a
crystal empirically. Diffusion and integration equations can be derived as well, but the
overall model relies on growth rate constant(s) and the concentration of the molecule. To
fully understand crystal growth however, molecular growth models are necessary.
Diffusion kinetics are well studied and understood, dependent on temperature, viscosity,
and intermolecular interactions with the solvent and other solute molecules; all of which
can be measured and/or determined experimentally. Integration is more complex and
there are two major models for crystal growth. The first is the attachment of molecules
via "favorable sites." These sites are essentially defects in the crystal surface which
provide the highest possible number of interactions for the attaching solution molecule as
compared to adhering to a clean crystal surface. Figure 1-17 illustrates some of these
defects which can lead to these energetically favorable sites.
The crystal growth rate will be dependent on the density of these sites and this
gives rise to the growth rate constant factors within derivations of growth rates. It has
been shown that underlying the mechanism is the surface diffusion of molecules to reach
these favorable sites. Spiral growth, as seen in Figure 1-18, is one such consequence of
this mechanism.
The growth of crystals via kinks and steps features new molecules being added to
the crystal layer by layer. The addition of a molecule to a kink site will create another
kink site directly adjacent to it. The spiral growth seen in Figure 1-18 above outlines this
mechanism through a screw dislocation in the crystal structure. The screw dislocation is
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constantly preserved as the addition of another molecule creates a new kink and favorable
reaction site in a circular pattern around the screw dislocation (Figure 1-19).42
The second molecular model is simplistically the ideal case where a new molecule
being incorporated in the crystal lattice directly onto a new, clean crystal surface. While
this is energetically unfavorable compared to the attachment sites outlined above, this
type of growth has been demonstrated to occur and once a single molecule is
incorporated, growth can occur similarly to the first model. This model is known as 2D
nucleation and growth and initially requires a higher supersaturation threshold to be
breached, in order for the new molecule to adhere and subsequently grow.42, 43
Figure 1-20 demonstrates 2D nucleation both schematically (a) and experimentally
(b). Overall, the growth mechanisms outlined here are not usually the rate-limiting step
in crystallization, especially at high supersaturation levels. However, as we examine the
effect on the system through the addition polymers to inhibit different aspects of the
system, we must consider the differences between nucleation and crystal growth as they
are two unique, albeit interconnected, processes.

1.4.3

Precipitation

Crystallization is the end result of precipitation from a supersaturated solution.
The previous sections outlined the mechanisms for crystallization but some systems have
been observed to exhibit ambiguous behavior, suggesting the precipitation of metastable
forms as a precursor to crystallization. Precipitation experiments are usually conducted
to investigate the time until crystallization occurs.

The use of polymers to inhibit

crystallization allows the supersaturation of a solution to be prolonged. However, the
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resulting precipitation profiles must be carefully examined to differentiate between
crystallization and precipitation to a non-crystalline phase.
In addition to the work done within the Taylor lab, other studies have shown a
change in precipitation behavior based on the presence and type of polymers within the
system. In one study, an extensive group of polymers was used to try and alter the
precipitation behavior of a model compound, danazol. The authors noted different types
of precipitation behavior and classified each of the polymers studied based on the
characteristics of the precipitation curve observed, where precipitation was characterized
using turbidity measurements.44
Figure 1-21 shows the differing precipitation profiles obtained from turbidity data
of danazol/polymer solutions. The data clearly showed different “types” of precipitation
and the authors claim that they are all part of a single precipitation behavior, albeit with
different parts exaggerated (such as the growth phase or the lag phase). However,
turbidity data does not give any insight into the actual phase of the precipitate whether it
is crystalline or amorphous (LLPS).44 LLPS was not taken into consideration in these
studies, even though LLPS is most widely observed in aqueous solutions of hydrophobic
drugs.
Other studies discuss the occurrence of promiscuous aggregation, observed during
high throughput screening assays with the colloidal species characterized as submicron
aggregates; LLPS is the most likely explanation for this behavior.44-46 Thus the ability to
determine and differentiate both crystallization and LLPS events within a system is
important to understand the overall phase behavior of supersaturated systems.
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The increase in high through-put screening assays to try and assess the impact of
polymers on the precipitation behavior of the drug combined with the use of
indiscriminate analytical techniques that fail to properly identify the phase characteristics,
had led to the need for more studies in this area.

1.5

Liquid-Liquid Phase Separation

There can come a point within a given system where two substances are no longer
miscible or able to coexist as one homogeneous phase. Thus, when a molar ratio of two
species is reached where homogeneous mixing is no longer favorable, they can
spontaneously separate into two distinct phases within the same system. Most commonly
this is observed in liquid systems and this phenomenon is called liquid-liquid phase
separation (LLPS), oiling out,47 or liquid-liquid demixing.48
LLPS has been observed and studied thoroughly in many different systems.
Classically, two partially miscible solvents undergo LLPS when they exceed their
miscibility limit e.g. octanol and water. The chemistry of the molecules and their ability
to form favorable interactions with the other component will impact if a system is
partially or fully miscible.
The phase diagrams depicted in Figure 1.22 all demonstrate the regime where LLPS
occurs. Diagrams (a) and (c) illustrate experimental evidence of LLPS either through the
coexistence of two distinct liquid phases (a), or the LLPS boundary curve and subsequent
spinodal curve (c). Diagrams (b) and (d) are theoretical representations of LLPS showing
the submerged LLPS boundary (b), and intersecting meta-stable zones for LLPS and
crystallization. Overall, each drug system will have a unique phase diagram that will
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depend on the physicochemical properties and interactions of the drug and the aqueous
solution.7
As for crystallization, there is an energy barrier for nucleation of a new liquid phase
from the homogenous solution phase that must be exceeded for LLPS to occur. The
behavior of mixing two liquids can be described by the Gibbs free energy of mixing,
Equation 1-17.
∆𝐺𝑚𝑖𝑥 = 𝑥𝐴 (𝜇𝐴 − 𝜇𝐴∗ ) + 𝑥𝐵 (𝜇𝐵 − 𝜇𝐵∗ )
Equation 1-17
The Gibbs free energy of mixing, ∆𝐺𝑚𝑖𝑥 , is determined by the mole fraction of each
substance, (𝑥𝐴 and 𝑥𝐵 ), the chemical potential of both substances (𝜇𝐴 – 𝜇𝐵 ), and their
respective reference chemical potentials (𝜇𝐴∗ – 𝜇𝐵∗ ). While the chemical potential of a
given substance within a multi-component system is not always easily extracted, the
overall phenomenon of LLPS depends on the variation in the chemical potential with
composition. LLPS can occur via two different mechanisms;


1) LLPS occurs when the ∆Gmix is greater than 0. The free energy associated with
mixing the two liquids together is higher than the free energy of the two liquids
completely separated.

Thus in this situation, the two liquids are completely

immiscible and cannot create a single, homogeneous liquid phase. This situation
is regarded as theoretical as all liquids are miscible to some extent.


2) LLPS can also occur when the ∆Gmix is negative (i.e. mixing is
thermodynamically favored relative to the unmixed states). In this situation, there
comes a mixture ratio of the substances that minimizes the free energy of the
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system and this can occur at two different ratios, creating a miscibility gap.
Compositions within this gap have a higher free energy relative to the minimized
energy points, and thus are less stable than a two phase system. Figure 1-23
shows this energy diagram for a partially miscible system.47
A system which shows partial miscibility before LLPS occurs exhibits the behavior
shown in Figure 1-23, in that the system will be miscible at certain ratios, and
thermodynamically unstable or metastable between a set of minima referred to as the
binodal points. These binodal points are the limits defining when LLPS can occur within
a given system.

1.5.1 Binodal/Spinodal of LLPS
Similar to crystallization as discussed earlier, above the binodal, the system has a
thermodynamic driving force towards a phase transition, in this case LLPS. However,
there exists a metastable region where an energy barrier must be overcome for LLPS,
∗
between the binodal (𝑥𝐴𝐵 , 𝑥𝐵𝐴 ) and a second barrier, known as the spinodal points (𝑥𝐴𝐵
,
∗
𝑥𝐵𝐴
).

Beyond the spinodal points, the system is completely unstable and will

spontaneously separate into two distinct phases without any thermodynamic barrier. In
summary, LLPS can occur beyond the binodal by overcoming an energy barrier and will
occur beyond the spinodal.
LLPS can often be easily detected visually as the separation of the system into two
liquid phases with LLPS being widely observed for organic molecules.7, 40, 49, 50 Two
patterns of LLPS are typically observed;
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LLPS occurs when the solute is dissolved in a cosolvent system, phase separation
to two liquid phases occurs and the solute is partitioned between each phase. The
concentration of the drug in each solvent is usually not equivalent and depends
largely on the drug molecule’s affinity for each given solvent (i.e. its solubility).
This type of LLPS is seen most often in the crystallization of drugs during
manufacturing7 and is not the subject of this research.



LLPS also occurs when one phase consists of mainly the solvent and a second,
liquid phase consists of mainly the drug in the form of a non-crystalline, viscous
phase.7 High drug concentrations and high temperature conditions can lead to
such phenomena occurring as seen in the example of vanillin and water system.51
It was shown that the concentration of vanillin exceeded a specific supersaturated
concentration, above which no more vanillin could exist within the water, thus the
vanillin underwent LLPS.

For systems that were kept close to the melting

temperature of vanillin (~80°C), LLPS is logical because vanillin should not exist
as a solid above the melting temperature. However, LLPS was also observed
below the melting temperature down to about 55°C.

It is logical that, for organic molecules, LLPS can occur above the melting
temperature, however, below the melting temperature, the anticipated second phase
created once the binodal is surpassed is the crystal since this is the thermodynamically
stable phase. However, there is evidence of LLPS occurring in systems far below the
melting temperature, leading to the hypothesis that the newly formed phase can be a
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supercooled liquid, or even a glassy amorphous phase. Phase separation to an amorphous
phase can thus occur at a high supersaturation when the free energy of creating a new
amorphous phase is lower than the free energy of the homogeneously mixed liquid
phases. The occurrence of LLPS for organic molecules below the melting temperature
has been widely documented although not extensively studied from a mechanistic
perspective. In the context of this research, the terms LLPS, oiling out, and liquid-liquid
demixing are all used to describe a system which now has two liquid phases, even if one
of those phases could potentially be classified as a super-cooled liquid.
LLPS in drug systems has been demonstrated for a variety of systems.7, 47-54 The
ability for LLPS to occur below the melting temperature results from the competing
effects of LLPS and crystal nucleation. If the kinetics of LLPS are faster than the
kinetics of crystallization, LLPS can occur in systems which exceed the binodal of the
system, leading to the creation of two liquid phases. Thus, these hydrophobic drugs
when mixed with water have a LLPS boundary concentration, above which LLPS will be
observed so long as crystallization does not occur. The drugs which have been shown to
undergo LLPS usually show the presence of drug-rich droplets.50
Initially, the system exists as a type of emulsion, with colloidal sized drug-rich
droplets dispersed in the water-rich phase.53 Over time, the droplets may coalescence and
form one continuous layer, and at any time can undergo crystallization. It is inherently
difficult to observe LLPS directly as the droplet size usually begins in the nanometer
region (100-300 nm). Dynamic light scattering (DLS) can detect and size the particles55
but limitations due to concentration of particles and crystallization may limit the
effectiveness of DLS. The presence of droplets also leads to turbidity of the system
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which can be detected through ultra-violet/visible spectroscopy but determining the
structure of the scattering phase can be challenging.28, 55, 56

1.5.2

LLPS and Drug Solubility

The creation of the new drug phase in the form of disordered drug-rich droplets
creates a new interface and equilibrium within the system. For multi-phase systems
which are partially miscible, the drug will be present in both the solvent phase and the
drug-rich phase. For drug systems the solvent is water, so let us consider aqueous
systems with a drug that has undergone LLPS. The following diagram illustrates the
different phases that can occur and their relationship, concentration-wise, with the other
phases.
The aqueous phase is shown to reach a maximum concentration of drug, above
which the system will spontaneously undergo LLPS. If the crystallization kinetics are too
slow to immediately compete with LLPS, then the drug-rich droplets, saturated with
water will be observed as the discrete, scattering phase. Theoretically, if this phase is
observed below the melting temperature it can be assumed that it should behave much
like a fully hydrated, super-cooled liquid amorphous phase. Determining the relationship
between the solubility (concentration) of the drug in the aqueous phase and the drug
phase is one of the major goals of this research, in order to determine if this is a
reasonable assumption.
The utilization of ASDs as solid oral dosage forms leads to supersaturation levels
that can yield different phase transitions, such as crystallization and LLPS.

40
Understanding the parameters and mechanisms for each is critical for formulating ASDs
and can lead to important new insight of drug dissolution behavior.

1.6

Overview of Research

The dissolution of ASDs leads to supersaturated drug solutions, crucial for increased
bioavailability especially for poorly soluble drug molecules. In other words, the solution
concentration is higher than the crystalline solubility. These solutions are therefore
thermodynamically metastable or unstable and can crystallize. Recent evidence suggests
that some systems can undergo another phase transformation, LLPS, prior to
crystallization. LLPS creates a discrete drug-rich phase dispersed in the continuous
aqueous drug-lean phase and is expected to impact the bioavailability of the drug though
effects on diffusion and crystallization behavior. The ability to predict, evaluate, measure,
and understand LLPS within supersaturated drug solutions is thus critical to the
formulation and effectiveness of ASDs. Polymeric additives have been shown to inhibit
crystal nucleation and crystal growth, which could promote LLPS. These observations
have led to the following hypotheses regarding these systems:


The apparent amorphous solubility, which can be achieved in formulations such
as amorphous solid dispersions, sets an upper-limit of supersaturation above
which LLPS will occur.

The LLPS boundary concentration is inherently

correlated to the amorphous solubility and these values can be both predicted and
observed for a given system if crystallization can be prevented over the timeframe
of the experiment.
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It is further hypothesized that drug-polymer interactions within these highly
supersaturated systems will lead to the stabilization of the liquid-liquid phase
separated system.



Ultimately, it is expected that solubility, phase transformation, and dissolution
rate information will correlate with mass transport across a membrane with the
LLPS concentration corresponding to the upper limit in the diffusion rate. This
analysis should yield a new perspective on the overall solubility enhancement
achieved through the formulation of amorphous solid dispersions of drugs which
can undergo LLPS.

The first chapter presented the essential background information relevant for this
research.

Chapter two examines the supersaturation behavior of a model drug and

polymers. This chapter is a detailed method development to detect the presence of LLPS
and crystallization from supersaturated drug solutions both qualitatively and
quantitatively. Chapter three contains a detailed characteristic analysis of the drug-rich
droplets formed during LLPS and the impact on the free-drug concentration. The effect
of polymers on LLPS was investigated with regards to the amorphous solubility and
drug-rich droplet characteristics. In chapter four, the dissolution behavior of ASDs was
evaluated with the same methods used in chapter two. The results were correlated to the
supersaturation results obtained from chapter two to determine presence and effects of
LLPS upon ASD dissolution. Lastly, chapter five investigated the impact of crystal seeds
on the dissolution performance of specific drug-polymer ASDs.

The relationship
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between the dissolution rate of the amorphous drug and the growth rate of the crystalline
drug was shown to impact the extent of supersaturation.
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1.7

Figures

Figure 1-1 Diagram of a unit cell within a crystal lattice.
.

44

Figure 1-2 Surface Free Energy vs Internal (Volume) Free Energy 57
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Figure 1-3 Theoretical polymorph phase diagram depicting enantiotropic and monotropic
polymorphs.58
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Figure 1-4. Energy vs. temperature diagram of amorphous solids relative to liquids and
solids Taken from 59, adaptation of diagram found in Ref 60.

Figure 1-5. Visual representation of the molecular arrangement of a crystalline solid,
amorphous solid, and gas.61
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Figure 1-6. Competing effects upon the crystallization of amorphous solids.4

Figure 1-7. Competing processes during the dissolution of drugs.62
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Figure 1-8. A schematic representation of the molecular level of an amorphous solid
dispersion. The lines represent the polymers and the circles represent the drug molecules.

Figure 1-9. Enthalpy vs. Temperature Phase Diagram
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Hmix and Smix

Figure 1-10. Diagram of the solubilization of a solid.63
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Figure 1-11. Simplified Solution Phase Diagram
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Figure 1-12. Amorphous vs Crystalline Dissolution-Time Profiles6
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Figure 1-13. Dissolution-Time Profiles of ASDs of felodipine with HPMC (90%
polymer:10% drug - black squares; 50:50 - red circles) and PVP (90:10 – blue triangles;
50:50 – white diamonds).29
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Figure 1-14. Example dissolution profile of a “spring and parachute” formulation, most
commonly formulated as an ASD.2
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Figure 1-15. Illustration of the thermodynamic effects of formation of a crystal. 𝑛 –
number of molecules in crystalline nucleus; ∆𝜇 − solution supersaturation (chemical
2
potential difference); 𝛼 – surface free energy (6𝑛 ⁄3 is a shape factor); ∆𝐺 – free energy.
* denotes critical cluster size.12
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Figure 1-16. (a) The two ordered processes necessary for nucleation to occur through
changes in concentration and structure. (b) A visual representation of two-step nucleation.
(c) Free-energy reaction plot depicting the energy involved in creating crystals from
solution depicting two types of two-step nucleation.38
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Figure 1-17. Favorable sites of integration during crystal growth.42

Figure 1-18. Spiral growth of crystalline insulin.
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Figure 1-19. Screw dislocation and subsequent spiral crystal growth due to the layering
around the dislocation.42

Figure 1-20. 2D Nucleation. (a) Schematic of 2D nucleation and growth.43 (b)
Experimentally observed 2D nucleation of ferritin.42
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Figure 1-21. Examples of different precipitation profiles of danazol/polymer systems
through turbidity measurements.44
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Figure 1-22. Four different types of phase diagrams depicting crystallization and liquidliquid phase separation (LLPS) for various small organic molecules.7
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Figure 1-23. Gibbs free energy function one a system exhibiting LLPS.47

Figure 1-24. Phase Diagram of vanillin (L2 and S) and water (L1).51
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Figure 1-25. LLPS (left) of an experimental drug in an aqueous system and the
subsequent crystallization over time (middle and right) at the expense of the droplets.50

Figure 1-26. LLPS of an experimental organic molecule shown to exhibit LLPS in the
form of droplets within an aqueous system.53
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Figure 1-27. Simple diagram of the relationship of different phases within a
supersaturated solution. Zone I is the stable zone below the crystalline solubility. Zone
II is the "metastable" zone where crystallization can occur. Zone III is the labile zone
above the amorphous solubility where crystallization and LLPS can occur.
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CHAPTER 2. IMPACT OF POLYMERS ON THE PRECIPITATION BEHAVIOR OF
HIGHLY SUPERSATURATED AQUEOUS DANAZOL SOLUTIONS

2.1

Abstract

The phase behavior of supersaturated solutions of a relatively hydrophobic drug,
danazol, was studied in the absence and presence of polymeric additives. To differentiate
between phase separation to a non-crystalline phase and phase separation to a crystalline
phase, an environmentally sensitive fluorescent probe was employed. Induction times for
crystallization in the presence and absence of polymeric additives were studied using a
combination of ultraviolet and fluorescence spectroscopy.

It was found that when

danazol was added to aqueous media at concentrations above the amorphous solubility,
liquid-liquid phase separation was briefly observed prior to crystallization, resulting in a
short-lived, drug-rich non-crystalline danazol phase with an initial size of around 500 nm.
The addition of polymers was found to greatly extend the lifetime of the supersaturated
two phase system, delaying the onset of crystallization from a few minutes to a few hours.
Below a certain threshold danazol concentration, found to represent the amorphous
solubility, only crystallization was observed. Thus although the addition of polymers was
unable to prevent danazol from precipitating once a threshold concentration was
exceeded, they did inhibit crystallization, leading to a solution with prolonged
supersaturation. This observation highlights the need to determine the structure of the
precipitating phase, since it is linked to the resultant solution concentration time profile.
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2.2

Introduction

Current drug discovery techniques tend to identify candidate drugs with complex
structures which may pose significant formulations challenges.

In particular, an

increasingly large number of new drug compounds have extremely poor solubility in
water1, impacting the bioavailability of the drug. Various formulation approaches can be
employed to increase the apparent solubility and/or the dissolution rate of a drug within
the gastrointestinal tract. Amorphous solid dispersions (ASDs) are one such technique
and there are numerous examples illustrating the resultant increases in apparent solubility
and bioavailability.2-7 However, ASDs are inherently difficult to formulate because of
the thermodynamically high energy state of the amorphous form of the drug leading to a
high risk for transformation to the crystalline form.7
Additives can be combined with the drug in the ASD to aid in stabilization of the
formulation both in terms of crystallization during storage8 and during dissolution9-10 and
these excipients enable ASDs to be a viable formulation option for some compounds.
However, the dissolution behavior of ASDs is extremely complex and is not well
understood.10-11

Highly supersaturated systems, such as those created from the

dissolution of ASDs, may undergo multiple phase transformations.12-13 Thus, a more
complete understanding of the thermodynamics and kinetics of these systems is critical to
successfully use this approach for the delivery of poorly water soluble drugs.
The solubility advantage achieved using an amorphous drug has been described
previously.4,6-7,14 The maximum increase in apparent solubility that can be achieved upon
dissolution of an amorphous solid has been termed the amorphous solubility4 and can be
theoretically, and in some cases, experimentally determined.4,8,15-16 Dissolution of an
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amorphous solid will lead to a supersaturated solution which will return to an
equilibrium, saturated solution through nucleation and crystallization of the drug,5,7
whereby the extent of supersaturation reached, as well as the timeframe for crystallization
will vary tremendously from compound to compound and for different formulations.
Excipients (typically polymers) are used to stabilize ASD formulations by preventing the
nucleation and growth of the drug from the supersaturated solution phase.17-18 There is
mounting evidence that for some systems, dissolution of a formulation consisting of a
hydrophilic polymer containing a molecularly dispersed drug leads to the formation of a
highly supersaturated solution which can subsequently undergo liquid-liquid phase
separation (LLPS), prior to crystallization.16,19-20

LLPS is a widely observed

phenomenon in organic chemistry,20-23 but the mechanisms and variables which affect
LLPS are not well understood in the context of drug delivery. Thus investigating LLPS
in aqueous drug solutions is vital to understand the complicated phase transformations
which can occur in supersaturated solutions which commonly arise following the
dissolution of solubility enhancing formulations, such as amorphous solid dispersions.
In this study we examined the phase behavior of supersaturated solutions of a
relatively hydrophobic drug, danazol. Danazol has been extensively investigated in terms
of the dissolution of the amorphous material, its precipitation behavior from
supersaturated solutions, and in bioavailability studies.18 To differentiate between phase
separation to a non-crystalline phase and phase separation to a crystalline phase, an
environmentally sensitive fluorescent probe was employed. Induction times for
crystallization in the presence and absence of polymeric additives were studied using a
combination of ultraviolet and fluorescence spectroscopy. For danazol, LLPS was briefly
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observed prior to crystallization. The addition of polymers was found to greatly extend
the lifetime of the supersaturated two phase solution, delaying the onset of crystallization
from a few minutes to a few hours. Below a certain threshold danazol concentration,
found to represent the amorphous solubility, only crystallization was observed.

2.3

MaterialsDanazol was purchased from Euroasia Chemicals (Euroasia Ltd, China)

and the molecular structure is presented in Figure 2-1. Polyvinylpyrrolidone (PVP)
K29/32 was purchased from Sigma Aldrich (St. Louis, MO), while hydroxypropylmethyl
cellulose (HPMC) 606 grade and hydroxypropylmethyl cellulose acetate succinate
(HPMC-AS) MF grade were supplied by Shin Etsu (Shin-Etsu Chemical Co., Ltd.,
Tokyo, Japan). Methanol was purchased from Macron Chemicals (Phillipsburg, New
Jersey). The aqueous media used in all experiments was 10 mM pH 6.8 phosphate
buffer. Pyrene at a concentration of 2 µM was added to some solutions for fluorescence
measurements; pyrene was purchased from Sigma Aldrich (St. Louis, MO). Polymer
concentration was 10 µg/mL (0.001% w/v) for all experiments.

2.4
2.4.1

Methods
Solubility

The equilibrium solubility of danazol was determined by high performance liquid
chromatography (HPLC).

An excess amount of drug was added to 10mM pH 6.8

phosphate buffer at 25°C and agitated for 48 hours. The supernatant was separated from
excess solid in solution by ultracentrifugation at 40,000 rpm in an Optima L-100 XP
ultracentrifuge equipped with Swinging Bucket Rotor SW 41 Ti (Beckman Coulter, Inc.,
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Brea, CA) for 15 minutes. The supernatant was diluted and solution concentration was
determined using an Agilent HP 1260 HPLC system (Agilent Technologies, Santa Clara,
CA). The chromatographic separation was performed with a ZORBAX Eclipse Plus C18
column (4.6mm x 100mm, 5µm). Danazol was detected by ultraviolet (UV) absorbance
at a wavelength of 288 nm. The mobile phase consisted of water, acetonitrile, and
methanol (40:30:30 by volume). The total analytical run time was 15 minutes and the
mobile phase flow was held constant at 1.0 mL/min. The injection volume was 50 µL.
Standards (0.1-100 µg/mL) were prepared in methanol and all samples were analyzed in
triplicate. The standard curve exhibited good linearity (r2 > 0.999) over the concentration
range. The equilibrium solubility in solutions containing 10 µg/mL of PVP, HPMC, and
HPMC-AS was determined using the same method.

2.4.2

Amorphous Solubility Estimation

The theoretical amorphous solubility of compound in a given medium can be
approximated using certain physical properties and the crystal solubility in the same
medium. Thus the ratio of the amorphous solubility (σamorph) to that of the crystalline
solubility (σcrystal) can be estimated from5:
∆𝐺
𝜎 𝑎𝑚𝑜𝑟𝑝ℎ
[−𝐼(𝑎2 )] 𝑅𝑇
=
𝑒
𝑒
𝜎 𝑐𝑟𝑦𝑠𝑡𝑎𝑙

Equation 2-1
Where ∆G is the free energy difference between the amorphous and crystalline
forms of the drug, R is the universal gas constant and T is the operating temperature. The
term 𝑒 [−𝐼(𝑎2 )] was derived by Murdande et al.3-4,24 and represents the activity of the
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amorphous solute saturated with water. The free energy difference can be approximated
using the Hoffman equation where it is assumed that the enthalpy of the crystal and
supercooled liquid vary linearly with temperature15:
∆𝐺 =

∆𝐻𝑓 ∗∆𝑇∗𝑇
2
𝑇𝑚

Equation 2-2
The heat of fusion (∆Hf) and melting temperature (Tm) can be readily determined
from DSC analysis. T is the operating temperature and ∆T is the difference between the
melting temperature and operating temperature (Tm-T). The methods described by Baird
et al.25 were used to determine the heat of fusion and the melting temperature of danazol.
The amorphous solute activity term,

𝑒 [−𝐼(𝑎2 )] , was determined from the moisture

sorption profile of the amorphous drug and applying the Gibbs-Duhem equation as
described previously.26 Amorphous danazol was prepared via the quench-melt method
by melting 15-20 mg of danazol and subsequently quench cooling the melt with liquid
nitrogen. The moisture sorption profile was determined at 25°C using a TA Q5000
dynamic vapor sorption analyzer (TA Instruments, New Castle, DE). The Q5000 was
equipped with a humidity controlled chamber and thermobalance. The sample was dried
within the sample holder at 25°C and 0% humidity until the weight change was less than
0.01% over a 5 minute interval.

The moisture sorption isotherm was collected by

equilibrating the sample under a controlled relative humidity (RH) range from 5% RH to
95% RH in 5% intervals. Equilibrium was assumed to be achieved when the weight
change was less than 0.01% over 5 minutes at each RH step.
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2.4.3

UV Extinction Measurements

UV spectroscopy was used to determine the concentration at which LLPS occurs
as described previously.16 The UV extinction was measured at 350 nm as a function of
danazol concentration in order to determine when an increase in scattering occurred due
to the formation of the drug-rich colloidal phase. The samples analyzed consisted of 50
mL of aqueous buffered solution (10 mM phosphate buffer, pH 6.8) stirred at 200 RPM
and maintained at 25°C using a jacketed vessel fed by a Julabo MA water bath (Seelbach,
Baden-Württemberg, Germany). The aqueous solution concentration of danazol was
controlled by using a syringe pump to add small volumes of a stock solution of danazol
dissolved in methanol (4 mg/mL). When no polymers were present in the buffer, danazol
was added to the aqueous solution at a rate of 5 µg/mL/min in order to rapidly attain the
LLPS concentration prior to crystallization occurring. For solutions containing polymers,
the addition rate was 1 µg/mL/min.

2.4.4

Fluorescence Spectroscopy using an Environmentally Sensitive Probe

Fluorescence spectroscopy can be used to determine the presence of the noncrystalline drug-rich phase created upon liquid-liquid phase separation by analyzing the
changes in the emission spectra of an environmentally sensitive fluorescent probe.12 For
pyrene, a hydrophobic fluorescent probe molecule, the emission spectrum varies
depending on the hydrophobicity of the local environment.27 The premise of these
measurements is that pyrene, acting as an environmental probe, will partition into the
more hydrophobic drug-rich phase created during the process of LLPS. The use of pyrene
to characterize surfactant micelle formation,28-29 as well as probe lipid bilayers,30-31 is
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widely established. Based on this body of literature, as well as previous studies from our
group using pyrene, a change in the ratio of two characteristic pyrene emission peaks (I1
at 373 nm, I3 at 383 nm) was used to indicate a change in the probe environment and
consequently the LLPS concentration.
The aqueous systems studied consisted of buffer, 2 µM pyrene and 10 µg/mL
polymer for experiments where polymer impact was evaluated. Fluorescence spectra
were collected for danazol solutions with concentrations ranging from 0-30 µg/mL.
Solutions were prepared via the solvent shift method by adding a small aliquot of a
methanolic solution of danazol (2 mg/mL) into the aqueous solution. The volume of the
final solution was approximately 10 mL and the temperature was maintained at 25°C
using a jacketed vessel and the sample was stirred at 200 RPM. Samples were withdrawn
from this solution after 30 seconds and 15 minutes and analyzed using a Shimadzu RF5301pc Spectrofluorometer (Kyoto, Japan). The excitation wavelength was 332 nm, and
the emission spectrum was collected at 0.2 nm intervals from 350-420 nm.

The

excitation slit width was 10 nm, while the emission slit width was 1.5 nm. Triplicate
measurements were made. Control experiments were performed by adding crystalline
drug (approximately 1 mg/mL) to aqueous buffer with and without polymer, and
containing 2 µM pyrene. In addition, the emission spectrum of pyrene in an amorphous
film of anhydrous danazol was obtained by spincoating a solution containing a
methanolic 40 mg/mL danazol and 0.1 mg/mL pyrene onto a quartz coverslip. The
transparent film was then evaluated using the fluorimeter described above.
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2.4.5

Simultaneous Ultraviolet (UV) and Fluorescence Spectroscopy

Fluorescent spectroscopy and UV spectroscopy were performed in parallel with
the aim of determining the induction time for crystallization in supersaturated danazol
solutions. For UV measurements, the spectrum was obtained using a fiber optic dip probe
with a pathlength of 1 cm coupled to a SI Photonics UV/Vis Spectrometer (Tucson, AZ)
Standard solutions of danazol (1-100 µg/mL) were prepared in methanol resulting in a
linear standard curve (r2 > 0.999). Measurements were recorded at two wavelengths; the
maximum UV absorbance wavelength of danazol of 288 nm, and at 350 nm where no
absorption is observed. Monitoring at 350 nm enables changes in the extinction due to
scattering to be readily observed. Fluorescence spectroscopy measurements were
performed on the same solution as described above. The samples analyzed consisted of
200 mL of aqueous buffered solution (10 mM phosphate buffer pH 6.8, 2 µM pyrene),
stirred at 200 RPM and held at 25°C using a jacketed vessel fed by a Julabo MA water
bath. Supersaturated solutions of danazol were created by the solvent shift method,
adding a small aliquot of a 4 mg/mL methanolic solution of danazol. The polymer
concentration was 10 µg/mL. For UV measurements, spectra were obtained every 30
seconds. 2 mL aliquots were extracted and analyzed in the fluorometer at various time
points.

2.4.6

Dynamic Light Scattering (DLS)

The particle size and zeta potential of the colloidal droplets formed in highly
supersaturated danazol solutions was determined with DLS. Each sample consisted of 50
mL of aqueous buffered solution (10 mM phosphate buffer pH 6.8, with and without 10
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µg/mL polymer). The solution was stirred (200 RPM) and the temperature was held
constant at 25°C using a jacketed beaker and water bath. Supersaturated solutions of
danazol were obtained as described above.

0.5 mL samples of the solution were

withdrawn at different time points and analyzed using a Nano-Zetasizer (Nano-ZS) from
Malvern Instruments (Westborough, MA) equipped with dispersion technology software
(DTS). A backscatter detector was used and the scattered light was detected at an angle
of 173°. Particle size data were obtained using 12mm square polystyrene disposable
cuvettes and zeta potential data were obtained using disposable capillary cells.

2.4.7

Induction Time Experiments using Second Harmonic Generation

Second harmonic generation (SHG) was used to detect the onset of crystallinity in
the solutions and to confirm that the initial scattering observed with UV extinction
measurements was due to a non-crystalline phase. Chiral crystals result in the frequency
doubling of light when analyzed under certain conditions, while solutions and disordered
materials do not. Therefore, the crystallization of SHG-active compounds can be detected
by the technique of second order non-linear optical imaging of chiral compounds
(SONICC).32-34

Supersaturated danazol samples below and above the LLPS

concentration were examined using the SONICC instrument manufactured by
Formulatrix (Waltham, MA). Supersaturated solutions containing danazol concentrations
of 10 μg/mL and 50 μg/mL were generated as described above at a 10mL scale. 100 μL
aliquots were then dispensed into a BD Falcon 96-well plate and loaded into the SONICC
instrument.

There was a delay of 30-60 seconds from the initial generation of

supersaturation until the first scan. The field of view was approximately 2 mm by 2 mm
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and wells were scanned from the bottom up to the meniscus at approximately 40 μm
increments in the Z direction, in order to capture crystallization occurring in different
volume elements of the well.

2.5
2.5.1

Results

Danazol Solubility

Select properties of danazol are shown in Table 2-1. The aqueous solubility of
crystalline danazol at 25°C, 10 mM pH 6.8 phosphate buffer was determined to be 0.9
µg/mL. Using the values of the crystal solubility, the melting temperature, and heat of
fusion (Table 1), the amorphous solubility is estimated to be 16 µg/mL at 25°C, and
hence the ratio of the amorphous to crystalline solubility is 19.6. This estimate contains
errors introduced by the assumptions inherent in the Hoffman equation,16 and errors in
the determination of the crystalline solubility, but is in reasonable agreement with that of
Ozaki et al., (19.6 vs 13.7)35 who also included a moisture correction factor and both of
these values are much lower than the estimate of Murdande et al which is 26.5.4
Table 2-2 shows the impact of low concentrations of polymer on the aqueous
solubility of danazol and the resultant amorphous solubility estimates. Within the error of
the measurements, it is apparent that HPMC-AS and PVP have negligible impact on
solubility, while HPMC increases the solubility by an appreciable amount.

2.5.2

Determination of LLPS concentration using UV extinction measurements.

It has been shown previously, that, in the absence of crystallization, the
concentration where LLPS occurs can be determined using UV spectroscopy.16,36 For a
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solution of danazol with no polymer (Figure 2-2), it is apparent that there is very low
total extinction at a non-absorbing wavelength at concentrations below approximately 13
µg/mL, while above this concentration, the solution scatters light and the extinction
increases. These measurements suggest the formation of a new phase when the
concentration of danazol exceeds ~13 µg/mL. The formation of this new phase occurs at
somewhat lower concentrations when low concentrations of polymers (PVP, HPMC,
HPMC-AS) are present (Figure 2-2). The concentration where the extinction increased
for each system was estimated by fitting the data in the regions of low and high extinction
using linear regression analysis and determining the intersection of the two curves; results
are presented in Table 2-3.

2.5.3

Investigation of Solution Phase Behavior using Fluorescent Probe

To confirm that the new phase detected from the UV extinction measurements is a
non-crystalline phase, the emission spectrum of pyrene was evaluated as a function of
danazol concentration. The emission spectrum of pyrene is highly sensitive to the
hydrophobicity of the local environment. This is readily apparent from Figure 2-3 which
shows the emission spectrum of pyrene dissolved in different solvents. Specifically the
ratio of the first peak (I1 = 373nm) and the third peak (I3 = 383nm) can be used as an
indicator of the local environment whereby this ratio will decrease with an increase in
hydrophobicity of the environment.27 Thus the I1/I3 ratio for pyrene dissolved in water is
1.97 while in cyclohexane, the ratio is 0.66. If a non-crystalline danzol-rich phase is
formed, the expectation is that the hydrophobic pyrene molecule will partition into this
phase, and since danazol is more hydrophobic than water, the I1/I3 ratio should decrease.

83
All of the aqueous buffered systems studied had an I1/I3 ratio of 1.95 ± 0.03 prior
to the addition of drug. Thus the presence of polymers at a concentration of 10 µg/mL
did not affect the pyrene emission spectrum. Figure 2-4 shows the pyrene I1/I3 ratios as a
function of danazol concentration. In the absence of a polymer, the I1/I3 ratio remained
constant at around 1.95 until the danazol concentration exceeded 13 µg/mL. At higher
danazol concentrations, the ratio steadily decreased with increasing concentration until a
concentration of around 24 µg/mL was reached, when the ratio reached a minimum
value. The very abrupt change in the pyrene I1/I3 ratio when the concentration of danazol
exceeds 13 µg/mL is consistent with the formation of a new, non-crystalline phase of
danazol into which pyrene can partition. The plateau value suggests that at around 24
µg/mL, sufficient drug rich phase has been created so that the majority of pyrene has
partitioned into the drug-rich phase. The decrease in the pyrene I1/I3 ratio to 1.5 suggests
that the probe is in an environment of similar polarity to that of methanol (Fig 2-3). The
I1/I3 ratio for pyrene in an anhydrous amorphous film of danazol was found to be 1.4. The
slightly higher pyrene ratio observed in the aqueous environment during the precipitation
experiments can be attributed to the presence of some water in the drug-rich phase, which
makes the environment slightly more hydrophilic than in the pure danazol film.
Increasing the danazol concentration to 50 and 100 µg/mL did not further lower the I1/I3
ratio (data not shown). The formation of a new phase at concentrations exceeding 13
µg/mL danazol is consistent with the UV extinction measurements described above, and
occurs at a concentration close to the predicted amorphous solubility.
The presence of a polymer in solution appeared to result in the phase separation of
danazol at a lower concentration (Figure 2-4). The onset of LLPS was estimated from the
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change in I1/I3 ratio and results are shown in Table 2-3. PVP had a minor impact (LLPS
onset at 11 µg/mL) while HPMC and HPMCAS had a larger impact (LLPS onset at 9
µg/mL for HPMC and 8 µg/mL for HPMC-AS).

Good agreement was observed

between the fluorescence measurements and the UV extinction measurements.

2.5.4

Initial Evaluation of Danazol Crystallization

Based on a visual examination of the solutions, it appeared that danazol solutions,
in the absence of polymer, crystallized fairly quickly following the occurrence of LLPS;
particles could be seen after a few minutes. In order to confirm that crystallization was
occurring on a fairly short time scale, the I1/I3 ratios were compared as a function of
concentration immediately following the generation of supersaturation and after 15
minutes. It has been previously observed that upon crystallization, the I1/I3 ratio changes
back towards that observed for pyrene in water.12 Figure 2-5 shows a comparison of the
I1/I3 ratios initially, and after 15 minutes for different amounts of added danazol. For
danazol alone, after 15 minutes, the I1/I3 ratio (1.95 ± 0.03) is identical to the ratio
observed in pure water, for all danazol concentrations, strongly suggesting that the drug
has crystallized and thus the probe no longer experiences the more hydrophobic drug-rich
environment. In other words, when the drug crystallizes, pyrene is excluded from the
crystal into the aqueous solution.
In order to confirm the pyrene emission results, a second harmonic generation
(SHG) experiment was performed to evaluate the crystallinity of the system over time.
Figure 2-6 shows the enhanced focus SHG images for danazol solutions below the LLPS
concentration (10 µg/mL danazol) and above (50 µg/mL danazol). Neither solution
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exhibited SHG signal initially, with the SHG signal evolving between 5-15 minutes
indicating that this represents the crystallization induction time.
In contrast to the changes observed in the pyrene emission spectrum for the
danazol alone, when any of the three polymers was present, the I1/I3 ratio remained
constant for 15 minutes, and was much lower than the value obtained for the purely
aqueous environment, suggesting that the polymers inhibited crystallization of danazol
and the probe remained in the drug-rich phase. Consequently, more extended studies
were performed to evaluate the crystallization induction times of danazol in the presence
and absence of the polymers.

2.5.5 Crystallization Induction Times as a Function of Danazol Concentration and
Polymeric Additives.
Experiments were conducted to measure the crystallization induction times at
different added danazol concentrations. Three concentrations were evaluated, above (20
µg/mL ), just above (15 µg/mL), and below (10 µg/mL) the estimated LLPS
concentration. Based on theoretical considerations, it would be anticipated that the
nucleation rate would increase with increasing supersaturation. However, once the LLPS
transition occurs, the supersaturation will remain constant in the system, since
equilibrium between the two phases will exist. At the same time once LLPS occurs, the
solution changes from being homogeneous (single phase) to heterogeneous (two phase);
this can also impact the nucleation kinetics. Thus it is of interest to evaluate induction
times in these different solution regimes.
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Crystallization induction times were determined by measuring the UV response as
a function of time at a wavelength where danazol shows good absorption, in order to
observe decreases in absorption that would be consistent with phase separation to a
crystalline phase with a resultant decrease in the solution concentration. Changes in the
scattering properties of the solution were also monitored by measuring the extinction at
350 nm. The same solution was also monitored as a function of time by fluorescence
spectroscopy, adding pyrene and measuring the I1/I3 ratio. Figure 2-7 shows example UV
absorbance and fluorescence data for a supersaturated solution of danazol as a function of
time, in the absence of a polymer. The UV data shows an initial drop in signal followed
by a change in slope after about 5-10 min. The fluorescence data shows a relatively
constant I1/I3 ratio for about 5-10 minutes followed by a rapid increase. The initial
decrease in the UV signal is attributed to the rapid coalescence of the LLPS nanodroplets
(DLS data shown in Fig. 2-11 provides evidence of rapid coalescence) which will change
their absorption and scattering properties,37 thus impacting the UV signal. Small particles
will absorb UV light to a greater extent than larger particles in the submicron region. 37
Thus if the droplet size is rapidly increasing, the absorbance will decrease as observed in
this study. This decrease is not thought to be due to crystallization based on the
fluorescence data (as well as the SHG data presented above). Instead, the crystallization
induction time is taken as the time when the UV data show a change in slope,
simultaneous with the increase in the I1/I3 ratio. For the danazol solution at 10 µg/mL,
which is below the LLPS concentration, the solution is homogeneous and thus the UV
absorption data did not show the same initial changes (data not shown) and the induction
time was readily seen from the sudden decrease in absorption at around 5 minutes. In
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contrast, the fluorescence data provided little insight into the crystallization behavior of
this system since there is no danazol-rich phase, and hence the I1/I3 ratio is minimally
impacted by crystallization. Thus in the absence of polymer, and for the experimental
conditions studied, the induction time for danazol crystallization is around 5-10 minutes
at all three concentrations. The induction times are summarized in Table 2-4 and Figure
2-12.
For solutions containing a polymer, the crystallization induction time increased to
around 1.5 hours for PVP, to approximately 2.5 hours with HPMC and to 4 or more hours
for HPMC-AS (Table 2-4); the large variations in induction time are quite typical since
nucleation is a stochastic process.

Figures 2-8, 2-9, and 2-10 show the UV and

fluorescence kinetic measurements for a representative experiment for each system. The
UV data does not show such a dramatic steep initial decrease in signal when the polymers
are present; it is well known that polymers are effective at stabilizing colloidal
systems,12,38 thus it is inferred that droplet coalescence is reduced in the presence of the
polymers resulting in a more stable UV signal prior to crystallization. This is supported
by dynamic light scattering data, presented in Figure 2-11A which shows much less
change in the droplet size in the presence of the cellulosic polymers relative to for
danazol alone. Figure 2-11B shows zeta potential data for the droplets in the absence and
presence of polymer. Danazol droplets have a negative zeta potential. In the presence of
polymers, the zeta potential changes, indicating that the polymers are adsorbed at the
droplet interface. While the negatively charged HPMCAS increased the negative zeta
potential, the neutral polymers decreased the extent of the negative charge observed.

88
Neutral cellulose polymers have been observed to have a similar effect on decreasing the
negative zeta potential observed for talc particles following adsorption.39
Changes were also observed in the UV signal at 350 nm, consistent with a change
of scattering properties upon crystallization and the time of these changes are noted in
Table 2-4. The sharp decrease in the UV absorbance signal shows a good coincidence
with the increase in the I1/I3 ratio from the fluorescence measurements, for the systems at
a danazol concentration of 15 and 20 µg/mL. Interestingly, the final value of the ratio of
the I1/I3 pyrene peaks did not return to value observed for pyrene in water suggesting the
presence of some unknown pyrene-drug-polymer complex. In the absence of danazol,
the polymers did not affect the I1/I3 of pyrene in water, so this observation cannot be
explained by the formation of a pyrene-polymer complex. Control experiments were
performed using pure crystalline danazol added to aqueous solutions containing pyrene
and polymers. The I1/I3 ratio was not initially influenced in any systems but after 24
hours, systems with polymers showed a slight decrease in the I1/I3 ratio (Figure 2-14). It
is likely that the polymer adsorbs to the surface of the crystalline drug, and pyrene
interacts with the drug and polymer in this region. A similar observation has been made
for crystalline carbamazepine in the presence of a surfactant.40
The final UV concentration measured in the presence of polymers was around 2-3
µg/mL which is greater than the crystalline solubility of danazol (~1 µg/mL) but much
lower than the LLPS concentration. The 10 µg/mL danazol solutions are either below or
just at the LLPS concentration in the presence of the polymer and thus the fluorescence
method ceases to provide meaningful data and induction times are inferred solely on the
basis of the UV data. Induction times, taken as the time when the UV signal shows large
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changes as a function of concentration, or when the fluorescence I1/I3 ratio increases, are
summarized in Figure 2-12; good agreement is seen between the various methods.
Clearly, the systems containing HPMCAS have the longest induction times, taking 6
hours to crystallize as compared to around 5 min in the absence of polymer. PVP and
HPMC also substantially increase induction times to approximately 100 and 150 min
respectively. In general, the systems above the LLPS concentration have shorter
induction times than the one phase solutions; this can most clearly be seen in the case of
solutions containing HPMC; induction times in the absence of the polymers were too
short to make this distinction.

2.6

Discussion

As the use of solubility enhancing formulations becomes more widespread, it
becomes increasingly important to understand the phase behavior of highly
supersaturated solutions of poorly water soluble drugs. Supersaturation can be generated
by dissolution of amorphous solid dispersions,10 following dilution of a cosolvent
formulation,41 by changing the pH environment,42 or upon digestion of a lipid
formulation.43 It is important to note that supersaturation is fundamentally different from
solubilization; in a supersaturated solution, the solute concentration (chemical potential)
is higher than that obtained by dissolving the crystalline material in the same medium and
a thermodynamic driving force for crystallization exists, whereas in a solubilized
solution, the equilibrium crystalline solubility is increased leading to higher solution
concentrations (without an increase in solute chemical potential), but no possibility of
crystallization. From a drug delivery perspective, supersaturated solutions can improve
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flux across a membrane while solubilized systems do not enhance flux unless the rate
limiting step is dissolution.44-45 This has led to a great interest in solubility enhancing
strategies that generate supersaturated solutions, and the number of commercial products
that employ this strategy is increasing with recent examples including ASDs of
telaprevir45 and vemurafenib47.
When supersaturated solutions are generated, precipitation is often observed. The
term precipitation is used in a generic sense to define the formation of a new phase
without defining the structure of the precipitating material. Precipitation is widely
regarded as an undesirable event and there has been much exploration of precipitation
inhibitors.6,18,48 Additives can inhibit precipitation by two main mechanisms, either
decreasing the supersaturation of the system by increasing the equilibrium solubility, or
by inhibiting nucleation or growth of the crystalline phase. Although precipitation from a
solubility enhancing formulation is generally considered unfavorable, recent studies have
shown that precipitation to an amorphous form results in maintenance of supersaturation,
while precipitation to a crystalline solid results in a rapid depletion of the
supersaturation.42 Furthermore, it appears that precipitation is inevitable in some
instances because there is an upper limit to supersaturation that can be achieved for
hydrophobic drugs, dictated by the spinodal decomposition point; beyond which phase
separation is spontaneous and inevitable. For several compounds, the concentration at
which spontaneous precipitation occurred has been found to be very close to the
theoretically estimated amorphous solubility.16 In other words, if the amorphous
solubility is exceeded, precipitation to an amorphous material, via the process of liquidliquid phase separation occurs, that is if crystallization does not occur first.
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The implications of liquid-liquid phase separation on the subsequent
crystallization behavior of supersaturated solutions are not well understood. The colloidal
solutions generated following LLPS are supersaturated and crystallization can
theoretically occur from either the drug-rich or the solution-rich phase. In studies with
ritonavir, a slowly crystallizing compound, it was also noted that the crystallization
kinetics were different depending if the colloidal drug-rich droplets were present or
absent;16 induction times were shorter in the two phase system. The crystallization
kinetics of a two phase colloidal solution of ritonavir were also highly dependent on the
type of additives present with different additives either enhancing or delaying
crystallization.12 It is apparent that ASDs can generate the very high supersaturations
necessary for LLPS to occur upon dissolution, and colloidal species have been widely
reported in the solutions that evolve from these formulations.10,13,49-50 Thus it is clearly
important to understand the phase behavior of different compounds in highly
supersaturated solutions and the impact of polymeric additives on the phase behavior.
Danazol is an interesting compound because the initial precipitate, which is clearly noncrystalline based on the fluorescence and SHG data shown in Figures 2-6 and 2-13, is
very short lived in the absence of additives. However, the concentration at which a
precipitate first forms corresponds closely to the predicted amorphous solubility of
danazol, and this phase persists for around 5-10 min. It is thus possible to rapidly
generate the amorphous material in situ and, by noting the concentration at which a
precipitate first forms, obtain an experimental estimate of the amorphous solubility. In
contrast, in two studies where amorphous danazol was dissolved, the maximum solution
concentration observed was less than a quarter of the expected value, due to
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crystallization of the sample before dissolution was complete.3,35 Thus, using the
approach of creating amorphous danazol in situ by rapidly increasing the solution
concentration, we are able to verify that the experimental amorphous solubility of
danazol is in excellent agreement with the theoretically estimated value, providing
additional validation of the thermodynamic approach developed by Murdande et al and
described above (Equations 2-1 and 2-2).24
The impact of the polymers on the solution phase behavior of danazol is
interesting from two perspectives. First, in the presence of the cellulosic polymers, the
LLPS concentration is somewhat decreased. This is different from the example of
ritonavir where polymeric additives were not found to change the LLPS
concentration.12,16 Second, there is a huge increase in induction time for crystallization, in
particular in the presence of HPMCAS, but also for the other two polymers.

The

reduction in the concentration where LLPS is observed in the presence of the cellulosic
polymers suggests that the polymers are mixing with the drug-rich phase. This would be
expected to lead to a reduction in the activity of the drug in the drug-rich phase, similar to
the effect that absorbed water has (and discussed in detail by Murdande et al.)24 and thus
reduce the solute concentration where LLPS occurs. Unfortunately, our attempts to
quantitate the amount of polymer in the drug-rich phase were not very successful due to
the low amounts of material present. However, preliminary NMR experiments suggest
that the drug-rich phase contained around 10-20% polymer when formed in the presence
of HPMC. For the PVP samples, the amount of polymer was lower than the detection
limit of the method (around 10%). These results are consistent with the experimental
observations that HPMC had a much larger impact on the LLPS concentration than PVP.
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Clearly some polymer is present in the droplet phase, at least at the interface since the
polymers influence the droplet size evolution as well as the droplet charge, as shown in
Figure 2-11. The incorporation of the polymer into the drug-rich phase is expected to
impact the crystallization kinetics via at least two mechanisms. First, the rate of both
crystal nucleation and crystal growth increases with increasing supersaturation. If LLPS
occurs at a lower concentration, then the supersaturation in that system will be lower than
in the system which has a higher LLPS concentration, which will have a correspondingly
higher supersaturation. Thus for the HPMC and HPMCAS systems, the supersaturation is
lower than for the PVP and no polymer systems. The lower supersaturation of the
cellulosic polymer containing systems would contribute to a slower nucleation rate, since
the nucleation rate is highly dependent on the extent of supersaturation,51 and this would
explain the longer experimentally observed induction times. Supersaturation is further
reduced if the equilibrium crystalline solubility is increased by the presence of the
polymer, which occurs in particular for HPMC (Table 2-2). However, supersaturation
alone does not explain the observed data; for example, HPMCAS systems have a longer
induction time than HPMC, even though HPMC systems have a lower supersaturation.
Second, the incorporation of the polymers into the drug-rich droplet, and/or association of
the polymer at the droplet interface are also likely to be important in terms of disrupting
the nucleation process. This is particularly true in the context of heterogeneous nucleation
which will be favored at the droplet-aqueous interface. Association of an additive at the
interface would be expected to modify heterogeneous nucleation kinetics. In a study of
ritonavir crystallization in two phase systems, it was found that additives could either
shorten or increase nucleation induction times, depending on their structure.12 In
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particular, additives with bulky functional groups were found to be effective inhibitors,
while compounds with long hydrocarbon chains were found to promote nucleation. These
additives were not found to impact the supersaturation of the system.
There are considerable analytical challenges to be overcome in order to
differentiate between LLPS and crystallization, since the concentrations involved are so
low. These difficulties are exacerbated by the evolving properties of the colloidal system
with time which impacts the UV data in particular, as highlighted in Figure 2-13. Here it
can be seen that there is a substantial change in the signal both in a region of the spectrum
where both absorption and scattering occurs, and in a spectral region where the main
effect is scattering. Both absorbance and scattering are strongly dependent on the size of
the disperse species, and since this changes with time for the colloidal danazol solutions
(as shown by the DLS data in Fig 2-11), the UV spectroscopic signals also change. Thus
at an absorbing wavelength, the colloidal system both scatters and absorbs light, making
quantitative determination of solution concentration extremely challenging.52 To further
complicate the analysis, the polymers impact the size evolution of the colloidal species,
and hence the observed UV signals. Therefore it is challenging to fully characterize the
time dependent phase behavior of the danazol solutions relying solely on the UV data,
necessitating the implementation of orthogonal techniques. Indeed, it is quite likely that
the initial phase transformation to a disordered precipitate would be missed unless being
specifically sought, in particular when non-specific analytical methods relying on
changes in solution turbidity are used. We have found that the use of an environmentally
sensitive fluorescence probe appears to be a good complementary method to the UV
approach, enabling differentiation between danazol that has phase separated to a
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disordered colloidal phase or to a crystalline phase. Likewise, SHG analysis, which has
been shown to be able to detect extremely low amounts of crystalline material in solid
samples,33-34,52 is a valuable analytical technique to confirm both the initially noncrystalline nature of the turbid danazol solutions, and the induction time for
crystallization.

2.7

Conclusions

Aqueous solutions of danazol were found to undergo liquid-liquid phase
separation when the solution concentration exceeded the amorphous solubility, leading to
a two phase colloidal solution consisting of a disordered drug-rich danazol phase, and a
drug-lean aqueous phase. This system was short lived, and crystallization occurred within
a few minutes, reducing the solution concentration. The crystallization behavior of the
danazol solution could be modified by the addition of small amounts of polymers which
dramatically extended the lifetime of the supersaturated solution.
However, some polymers reduced the maximum extent of supersaturation that
could be achieved, both by increasing the equilibrium crystal solubility and by reducing
the amorphous solubility.

Thus the polymeric additives have both favorable and

unfavorable effects on solution phase behavior and kinetics. Understanding the complex
phase behavior of supersaturated aqueous solutions ultimately will provide greater insight
into amorphous solid dispersion formulation.
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2.8

Tables

Table 2-1. Select Physical Properties of Danazol
Property

Value

Molecular Weight

337.5 g/mol

Melting Temperature

225.4± 0.4°C

Tg

78.7±0.3°C

Aqueous Solubility at 25°C

0.9 ± 0.2 µg/mL

Heat of Fusion

28.9 ± 0.3 kJ/mol

Moisture Sorption Correction Factor (exp [-I(a2)])

0.935

Amorphous:Crystalline Solubility ratio at 25°C*

19.6

*Calculated using equation 1.

Table 2-2. Crystalline and estimated amorphous solubility of danazol in the presence and
absence of polymers at 25°C, n=3, errors equal one standard deviation. Amorphous
solubility values are estimated from the crystalline solubility in a given medium and an
amorphous:crystalline solubility ratio of 19.6.
System

Crystalline
Solubility
(µg/mL)

Estimated
Amorphous
Solubility
(µg/mL)*

Danazol

0.9 ± 0.2

16 ± 4

Danazol and PVP

1.3 ± 0.4

25 ± 8

Danazol and HPMC

2.2 ± 0.5

43 ± 9

Danazol and HPMC-AS

1.1 ± 0.4

22 ± 8

*errors determined using the standard deviations from the crystalline aqueous solubility
measurements
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Table 2-3. Summary of Amorphous Solubility/LLPS Onset Concentrations
Calculated
Amorphous
Solubility (μg/mL)

LLPS Concentration LLPS Concentration
via
Fluorescent via UV Extinction
Probe (μg/mL)
(μg/mL)

Danazol

16

13

13

Danazol and PVP

25

11

11

Danazol and HPMC

43

9

8

Danazol and
HPMCAS

22

8

8
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Table 2-4. Crystallization induction times (Ti) for various danazol solutions.
Danazol

Ti

Ti

(min,

(min,

UV extinction)

fluorescence)

Ti
System

Concentration
(min, UV abs.)
(μg/mL)
10

10 ± 6

N/A

N/A

15

6±1

7±1

10 ± 2

20

7±3

10 ± 7

9±3

10

162 ± 25

N/A

N/A

15

112 ± 21

153 ± 37

120 ± 42

20

88 ± 18

107 ± 15

102 ± 17

10

285 ± 92

N/A

N/A

15

172 ± 4

111 ± 14

195 ± 21

20

163 ± 15

177 ± 21

167 ± 38

10

516 ± 167

N/A

N/A

Danazol:HPMCAS 15

365 ± 148

315 ± 35

370 ± 92

20

277 ± 138

303 ± 161

250 ± 69

Danazol

Danazol:PVP

Danazol:HPMC
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2.9

Figure 2-1. Molecular structure of danazol.
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Figure 2-2. UV extinction intensity at 350 nm as a function of danazol concentration
showing an increase in extinction at concentrations >10µg/mL for solutions containing
polymers and at a concentration >13µg/mL in the absence of polymer.
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Figure 2-3.The pyrene emission spectra in different solvents (top) and the resulting peak
ratios between two characteristic peaks, peak I1 and peak I3 (bottom).

102

2.0

DNZ Only
PVP
HPMC
HPMCAS

1.9

Pyrene I1/I3 Ratio

1.8

1.7

1.6

1.5

1.4
0

5

10

15

20

25

30

Added Concentration (µg/mL)

Figure 2-4. Pyrene I1/I3 ratios as a function of danazol (DNZ) concentration in the
presence and absence of 10 µg/mL polymer.
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Figure 2-5. Pyrene Emission Wavelength Ratios of Danazol in Solution
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Figure 2-6. Enhanced Focus SHG images of danazol supersaturated systems. Bright spots
indicate SHG signal and the area visualized is 2 mm by 2 mm. Top: 10 µg/mL danazol
solution at various time points. This concentration is below the expected LLPS
concentration. From left to right; 1 minute, 5 minutes, 12 minutes after generation of
supersaturation. Bottom: 50 µg/mL danazol solution at various time points. This
concentration is above the expected LLPS concentration. From left to right; 2 minutes, 5
minutes, 10 minutes after generation of supersaturation.
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Figure 2-7. UV absorbance apparent concentration (left axis, solid symbols) and pyrene
emission spectral ratios (right axis, open symbols) for a supersaturated solution of
danazol (concentration 20 µg/mL which is above the LLPS concentration).
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Figure 2-8. UV absorbance apparent concentration (left axis, solid symbols) and pyrene
emission spectral ratios (right axis, open symbols) for a supersaturated solution of
danazol (20 µg/mL) containing 0.01% w/v PVP.
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Figure 2-9. UV absorbance apparent concentration (left axis, solid symbols) and pyrene
emission spectral ratios (right axis, open symbols) for a supersaturated solution of
danazol (20 µg/mL) containing 0.01% w/v HPMC
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Figure 2-10. UV absorbance apparent concentration (left axis, solid symbols) and pyrene
emission spectral ratios (right axis, open symbols) for a supersaturated solution of
danazol (20 µg/mL) containing 0.01% w/v HPMCAS.
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Figure 2-13. Overlay of UV, Fluorescence, and SHG data for a single supersaturated
system of danazol (initial concentration of 20 µg/mL danazol; above LLPS concentration)
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CHAPTER 3. CHARACTERIZATION OF HIGHLY SUPERSATURATED
DANAZOL SOLUTIONS – IMPACT OF POLYMERS ON MEMBRANE
TRANSPORT AND PHASE TRANSITIONS

3.1

Abstract

Excipients are essential for solubility enhancing formulations. Hence it is
important to understand how additives impact key solution properties, particularly when
supersaturated solutions are generated by dissolution of the solubility enhancing
formulation. Herein, the impact of different concentrations of dissolved polymers on the
thermodynamic and kinetic properties of supersaturated solutions of danazol were
investigated. A variety of experimental techniques was used, including nanoparticle
tracking analysis, fluorescence and ultraviolet spectroscopy and flux measurements.
Neither the crystalline nor amorphous solubility of danazol was impacted by common
amorphous solid dispersion polymers, polyvinylpyrrolidone, hydroxypropylmethyl
cellulose (HPMC) or HPMC-acetate succinate. Consequently, the maximum membrane
transport rate was limited only by the amorphous solubility, and not by the presence of
the polymers. The polymers were able to inhibit crystallization to some extent at
concentrations as low as 1 μg/mL, with the maximum effectiveness being reached at 10
μg/mL. Aqueous danazol solutions formed a drug-rich phase with a mean size of 250nm
when the concentration exceeded the amorphous solubility, and the polymers modified
the surface properties of this drug-rich phase. The phase behavior of supersaturated
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solutions is thus complex and the kinetics of phase transformations can be
substantially modified by polymeric additives present at low concentrations. However,
fortunately, these additives to not appear to impact the bulk thermodynamic properties of
the solution, thus enabling supersaturated solutions, which provide enhanced membrane
transport relative to saturated solutions to be generated.

3.2

Introduction

Increasingly, potential drug candidates emerging from discovery programs have
complex molecular structures and properties. This in turn has led to an increase in the
prevalence of drugs with sub-optimal aqueous solubility.1 It is estimated that 75% of
pipeline drugs can be considered to have low aqueous solubility.2 Consequently, the
development and understanding of solubility enhancing techniques are pivotal to creating
effective formulations for these difficult to deliver compounds.

Amorphous solid

dispersions (ASD) are one such formulation approach which has been shown to increase
the effective solubility3-6 and bioavailability of poorly-soluble drugs.7-9 Upon dissolution
of an ASD, the solutions generated are typically supersaturated with respect to the
crystalline form solubility, and therefore have a thermodynamic driving force for
crystallization. Recently, it has been shown that ASDs can undergo a second phase
separation phenomenon in these highly supersaturated solutions as a precursor to
crystallization, known as liquid-liquid phase separation (LLPS).9-12 The resulting phase
transformation creates a colloidal dispersion, with one phase consisting of non-crystalline
water-saturated drug-rich droplets/particles dispersed within the second phase which
consists of an aqueous phase with a concentration equal to the amorphous solubility. Both
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phases are supersaturated and hence crystallization can subsequently occur.

The

mechanisms and formulation factors impacting the formation of this drug-rich phase are
not well understood, although it has been suggested that its presence could be important
in influencing the bioavailability and absorption of certain drugs.9,

13

It has been

demonstrated that LLPS of poorly water soluble drugs in aqueous media is a widespread
phenomenon that can occur following pH change, dissolution of ASDs, dilution of
organic solvent solutions, and by cooling of a supersaturated solution.12,

14-16

Furthermore, phase separation to a colloidal drug-rich phase during high-throughput
screening assays for new drug targets is also commonly observed.17-19
In order to study and understand the properties of the drug-rich phase produced by
LLPS in supersaturated solutions, it is necessary to stabilize the system against both
coalescence and crystallization, and to understand the impact of additives on these
processes. For example, surfactants and polymers have been found to influence both
coalescence and crystallization kinetics.11, 20, 21 Furthermore, it has also been noted that
excipients such as surfactants can impact both crystal solubility and the concentration at
which LLPS is observed,22 and therefore can also change the thermodynamic properties
of the solution.

Both the thermodynamic properties of the supersaturated solution, as

well as the kinetics of phase transformations are important considerations when designing
and evaluating solubility enhancing formulations.
In this study, the generation, thermodynamics and stability of solutions containing
drug-rich droplets of the model compound, danazol, were studied, in the presence and
absence of three polymers commonly used in amorphous solid dispersion formulations, in
order to better understand the properties of these colloidal solutions. The model polymers
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evaluated were polyvinyl pyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC),
and HPMC acetate succinate (HPMC-AS). Multiple analytical techniques were used to
evaluate the complex phase behavior and to delineate crystalline precipitation,
amorphous precipitation (in the form of drug-rich droplets), and free-drug solution
concentrations. The major goals of this work were to: (1) investigate the impact of
polymers on the thermodynamic properties of danazol solutions through measurement of
crystalline solubility, LLPS onset concentrations, and mass transport rate across a
membrane (flux measurements) and, (2) investigate the impact of polymers on the
kinetics of danazol phase transformations using crystallization induction time
experiments and characterization of the droplets as a function of time.

3.3

Materials

Danazol was purchased from Euroasia Chemicals (Euroasia Ltd., China), pyrene,
and polyvinyl pyrrolidone (PVP) K29/32 were purchased from Sigma-Aldrich (St. Louis,
MO),

while

hydroxypropylmethyl

cellulose

(HPMC)

606

grade

and

hydroxypropylmethyl cellulose acetate succinate (HPMC-AS) MF grade were supplied
by Shin-Etsu (Shin-Etsu Chemical Co., Ltd., Tokyo, Japan). Methanol, acetonitrile, and
dichloromethane were purchased from Macron Chemicals (Phillipsburg, NJ).

The

aqueous medium used in all experiments was 10 mM pH 6.8 phosphate buffer. Pyrene
was added to solutions at a concentration of 2 µM for fluorescence measurements.
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3.4
3.4.1

Methods

Solubility Measurements.

The aqueous solubility of danazol was determined using high performance liquid
chromatography (HPLC). An excess amount of crystalline danazol was added to 50 mL
of buffer. The solutions were agitated and allowed to equilibrate for 48 hours at 25°C.
The supernatant was then separated from the excess solid in solution via
ultracentrifugation for 15 min at 40,000 rpm in an Optima L-100 XP ultracentrifuge
equipped with Swinging Bucket Rotor SW 41 Ti (Beckman Coulter, Inc., Brea, CA).
The supernatant was diluted and the solution concentration of danazol was determined
using an Agilent HP 1260 HPLC system (Agilient Technologies, Santa Clara, CA). A
ZORBAX Eclipse Plus C18 column (4.6 mm x 100 mm, 5 μm) was used for
chromatographic separation and danazol was detected via ultraviolet (UV) absorbance at
288 nm. A volume of 50 μL was injected into a mobile phase consisting of water,
acetonitrile, and methanol (40:30:30 by volume) at a rate of 1.0 mL/min. The total
analytical time was 15 min. Standards (0.1 – 100 μg/mL) were prepared in methanol, and
all samples were analyzed in triplicate. The standards exhibited good linearity (r2 > 0.999)
over the concentration range.

The equilibrium solubility of danazol in solutions

containing 1, 10, 100, 1000 μg/mL of PVP, HPMC, and HPMC-AS was also determined
using this method.
The theoretical amorphous solubility was calculated via the method derived and
outlined by Sousa et al.23 The melting temperature, heat of fusion, glass transition
temperature, and heat capacity data were determined using differential scanning
calorimetry (DSC) as described previously24 using a TA Q2000 differential scanning
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calorimeter (TA Instruments, Newcastle, Delaware). Modification of the solute activity
by sorbed moisture was determined from the moisture sorption profile at 25 °C using a
TA Q5000 dynamic vapor sorption analyzer (TA Instruments, New Castle, DE) as
described previously.6, 20

3.4.2

LLPS Concentration Determination.

The concentration at which LLPS was observed for danazol was determined using
the following methods; UV extinction and fluorescent probe methods as described
previously,20 assay via ultra-centrifugation and HPLC analysis of the supernatant
concentration, and nanoparticle tracking analysis (NTA). The samples analyzed by UV
extinction spectroscopy (SI-Photonics UV spectrometer, Tucson, AZ, with a 1 cm path
length dip probe, extinction monitored at 450 nm) consisted of 50 mL of buffer stirred at
300 rpm and maintained at 25°C using a jacketed vessel fed by a Julabo MA water bath
(Seelbach, Baden-Wurttemberg, Germany).

The aqueous solution concentration of

danazol was continually increased by using a syringe pump to add small volumes of a
concentrated stock solution of danazol dissolved in methanol (5 mg/mL). Polymers (11000 μg/mL) were pre-dissolved in the aqueous buffer. Danazol was added to the
aqueous buffered solutions at a rate of 1 μg/mL/min. When no polymers were present in
the buffer, an aliquot of the danazol stock solution was added to create a starting solution
concentration of 5 μg/mL of danazol, in order to reach the concentration at which LLPS
occurred prior to crystallization using the same subsequent rate of addition (1
μg/mL/min).
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Pyrene was used as an environmentally sensitive fluorescent probe to evaluate the
evolution of different environments in the solution with different danazol concentrations.
Peaks I and III of the emission spectra were analyzed to determine if LLPS had occurred
within the solution. The expectation is that formation of a drug-rich phase will lead to
mixing of pyrene with this phase, and hence the emission spectrum will reflect a more
hydrophobic environment. The samples analyzed consisted of 50 mL of buffer with a
pyrene concentration of 2 μM. Polymer was pre-dissolved in the buffer (1-1000 μg/mL)
and danazol concentrations from 0-20 μg/mL were analyzed in 0.5 μg/mL increments.
Samples were stirred at 300 rpm and maintained at 25°C using a jacketed vessel fed by a
Julabo MA water bath (Seelbach, Baden-Wurttemberg, Germany).

Solutions were

prepared via the solvent shift method by adding small aliquots of a methanolic stock
solution of danazol (5 mg/mL) to the aqueous solutions. Samples were then withdrawn
after each subsequent addition of the stock solution and analyzed using a Shimadzu RF5301pc Spectrofluorometer (Kyoto, Japan). The excitation wavelength was 332 nm, and
the emission spectrum was collected at 0.2 nm intervals from 350-420 nm.

The

excitation slit width was 15 cm, while the emission slit width was 1.5 cm.
The

concentration

in

the

continuous

phase

was

determined

using

ultracentrifugation to pellet the drug-rich phase, followed by HPLC analysis of the
supernatant.

Samples consisted of 10 mL of buffer with varying amounts of pre-

dissolved polymer. An initial solution concentration of 15 μg/mL of danazol was added
via small aliquots of a methanolic stock solution of danazol.

The samples then

underwent ultracentrifugation using an Optima L-100 XP ultracentrifuge (Beckman
Coulter, Inc., Brea, CA) equipped with a Swinging Bucket Rotor SW 41 Ti. Samples
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were centrifuged at 35,000 rpm for either 30 minutes (polymer concentration < 100
μg/mL) or 60 minutes (polymer concentration ≥ 100 μg/mL) at 25°C. The resulting
supernatant of each sample was diluted at a ratio of 1:1 with a mobile phase of
water:acetonitrile:methanol (40:30:30 by volume). HPLC analysis was then performed
using the method described previously.

The ultracentrifuge method provides the

concentration of the drug in the continuous aqueous phase once phase separation is
complete and represents one of the binodal points.25
NTA was used to determine the concentration at which scattering species could be
observed using this methodology. Samples consisted of 10 mL of buffer at 25°C with
varying amounts of pre-dissolved polymer. Danazol was added using small aliquots of
the methanolic stock (5 mg/mL) to create varying final danazol concentrations (0-15
μg/mL). 1 mL samples of each solution were withdrawn and analyzed using a NanoSight
LM10 from Malvern Instruments (Westborough, MA) equipped with nanoparticle
tracking analysis software. The LM10 was equipped with a 75 mW green (532 nm) laser
and a temperature controlled flow through cell stage. Samples were analyzed for 60
seconds and camera settings were held constant throughout all experiments (screen gain =
2.0, camera level=7). The detection threshold upon analysis was also held constant (20)
for all experiments along with camera gain (5.0). The onset of LLPS was determined by
analyzing the observed light scattering particle concentration as a function of added
danazol concentration. All samples were analyzed in triplicate.
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3.4.3
A

side-by-side

diffusion

Flux Measurements.
cell

apparatus

(PermaGear,

Inc.

Hellertown,

Pennsylvania) was used to determine the flux of danazol solutions as a function of added
concentration, in the presence and absence of different amounts of dissolved polymer. A
regenerated cellulose membrane with a molecular weight cut off (MWCO) of 6-8 KDa
was used to separate the receiver and donor chambers. Each chamber had a maximum
capacity of 34 mL and was filled with buffer with pre-dissolved polymer (1-1000 μg/mL)
in both chambers. The orifice surface area was 7.065 cm2. The temperature for all
experiments was maintained by a recirculating water bath at 25°C. Supersaturation was
generated by adding aliquots of a methanolic stock solution of danazol (5 mg/mL) to the
donor

compartment.
A UV dip probe (2 cm path length) connected to a SI-Photonics UV spectrometer

was used to determine the apparent drug concentration in the solution for the receiver
chamber by monitoring the absorption peak at 288 nm as a function of time.
Concentration versus time plots were generated for the receiver chamber and the slope of
the line was estimated using linear regression. The flux across a membrane can be
estimated from the slope of the concentration versus time plots, assuming sink conditions
in the receiver chamber and constant concentration in the donor chamber.25 The flux can
be calculated via the following equation:

𝐽=

𝑑𝑀 𝐷𝑆𝑎
=
𝑑𝑡
ℎ𝛾𝑚

Equation 3-1
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The flux (J) is determined from the change in mass per unit time (dM/dt). This in turn is
dependent on the diffusion coefficient (D), the membrane cross-sectional area (S), the
solute thermodynamic activity (a), the activity coefficient of the solute in the membrane
(γm), and the thickness of the membrane (h). S, D, γm , h are constants using the
experimental setup described above. The activity of the drug is given by the following
equation:
𝑎 = 𝐶𝛾
Equation 3-2
The activity (a) is determined by the activity coefficient (γ) and the concentration
(C). Thus, the flux as determined from the slope of M versus t, is directly proportional to
the activity of the drug in solution. Flux data can be therefore used to assess the freedrug solution concentration of danazol in the donor chamber and determine if polymers
impact that danazol activity.

3.4.4 Induction Time Experiments.
The crystallization induction time was determined by UV spectroscopy as
described in previously.20,

26

Samples consisted of 50 mL of buffer containing pre-

dissolved polymer (1-1000 μg/mL). An initial danazol concentration of 15 μg/mL was
created via addition of a small aliquot of a methanolic stock solution of danazol (5
mg/mL). The apparent UV concentrations were measured via absorbance at 288 nm and
the induction times were determined as the time where an abrupt and sustained decrease
in the apparent solution concentration occurred.
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3.4.5

Characterization of the Drug-Rich Droplets formed via LLPS.

The size and zeta-potential of the drug-rich colloidal droplets formed during
LLPS were analyzed using dynamic light scattering (DLS). Each sample consisted of 10
mL of buffer with pre-dissolved polymer (1-1000 μg/mL). The solution was stirred (200
rpm) and the temperature was held constant at 25°C by placing a scintillation vial inside a
jacketed vessel connected to a water circulator. Supersaturated solutions of danazol were
prepared as described above. 0.5 mL of each solution was withdrawn and analyzed using
a Nano-Zetasizer (Nano-ZS) from Malvern Instruments (Westborough, MA) equipped
with dispersion technology software. A backscatter detector was used, and the scattered
light was detected at an angle of 173°. Particle size analysis data were obtained using 12
mm square polystyrene disposable cuvettes, and zeta potential data were obtained using
disposable capillary cells.
The size of the drug-rich droplets was also analyzed using nanoparticle tracking
analysis (NTA). Solution samples were prepared as for the for DLS analysis and were
analyzed using the same NTA parameters described above. Particle size distributions and
mean particle size was obtained for all systems studied.

3.5

Results

3.5.1 Danazol Crystalline Solubility
The impact of polymers, present at different concentrations, on the solubility of
crystalline danazol is summarized in Table 3-1. It is apparent that relatively minor
increases in solution concentration are observed even for the highest polymer
concentrations studied. The solubility value for danazol in buffer was used to estimate
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the amorphous solubility, and a value of 7.8 μg/mL was obtained. This is lower than the
previously reported estimated value of 16 μg/mL 20 This can be rationalized by the more
rigorous calculation method used in the current study. Use of heat capacity data has been
found to result in predictions of the amorphous solubility more in accordance with
experimental values.23
The concentration where LLPS occurs has been found to correlate with the
amorphous solubility for several compounds.12,

20, 23, 25

Methods previously used for

determining the onset concentration at which LLPS occurs involve measuring a change in
the solution properties as the concentration of drug is continually increased. These
methods have included UV extinction, where the formation of a new phase leads to
scattering at a non-absorbing wavelength, and using environmentally sensitive
fluorescence probes that mix with the newly formed drug-rich phase, and then show a
change in emission spectrum (i.e. they register a more hydrophobic environment) relative
to when dissolved in a single phase aqueous solution.11, 20, 25, 27 Herein, we have explored
two additional methods, ultracentrifugation to separate the two phase and determine the
concentration of the supernatant, and nanoparticle tracking analysis to directly detect at
what concentration the drug-rich droplets can be detected.
Nanoparticle tracking analysis tracks and analyzes individual particles/droplets
within a dilute solution. NTA was used to analyze different concentrations of danazol for
the presence of scattering centers beyond the background noise. Figures 3-1(a-c) show
frames captured from video whereby the light scattered from individual droplets/particles
is tracked as a function of time. Figure 3-1(a) shows that at a low concentration of 3
μg/mL, no scattering, is observed. At 8 μg/mL, there is evidence of a few scattering
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centers while increasing the concentration to 11 μg/mL shows an increase in the number
of droplets present in solution.
The images were processed to determine the particle concentration as a function
of danazol concentration, and data is summarized in Figure 3-2. Here is can be clearly
seen that, for danazol solutions in buffer, the particle count is very low at concentrations
up to 8 μg/mL, and increases steeply at higher concentrations.
Results obtained with the various techniques for danazol solutions in the presence
and absence of polymers are summarized in Table 3-2. In general, it can be seen that
there is good agreement between the various techniques. LLPS is observed at
concentrations of approximately 7-9 μg/mL danazol and no trend is discernable with
polymer type or concentration. If the polymers are substantially incorporated into the
danazol drug-rich phase and thus reduce the thermodynamic activity of danazol in the
system, it would be anticipated that the concentration where LLPS is observed would be
reduced. This does not appear to be the case for these systems, but in order to confirm
that the activity of the drug is unchanged in the presence of polymers, flux measurements
were conducted.

3.5.2

Flux Measurements

The relationship between flux and added danazol concentration was determined for
danazol in the absence of a polymer, and results are summarized in Figure 3-3. The flux
increases linearly with added concentration until a concentration of 8 μg/mL. Above this
concentration, the flux is constant within experimental error.

It has been shown

previously, for a number of systems, that the concentration at which the flux rate plateaus
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correlates to the concentration at which LLPS occurs,25 because the system has reached
the maximum free-drug solution concentration. Addition of more compound beyond this
concentration, leads to the formation of more of the drug-rich phase, which does not
contribute to the observed flux. From the flux data, the measured LLPS concentration for
danazol in the absence of a polymer is 8 µg/mL.
Corresponding flux measurements were then obtained for solutions containing
different amounts of polymer, in order to determine if the presence of the polymer
reduced the maximum free drug concentration. Figure 3-4 shows a summary of the
maximum flux values obtained for various danazol-polymer solutions. If the polymer was
substantially mixing with the drug-rich phase, depressing the danazol concentration at
which it forms, it would be expected that the flux would decrease in the presence of the
polymers. Within experimental error, it is apparent that the polymer do not reduce flux
across the concentration range studied, and thus the polymer does not impact that free
drug concentration. This can also be seen from Fig. 3-3, where the maximum flux from
danazol solutions containing 10 μg/mL of polymer overlap the maximum flux seen for
danazol alone.

3.5.3

Kinetic Fluorescence Experiments

Previously, it was reported that the concentration at which LLPS was observed, as
determined using a fluorescent probe, decreased in the presence of dissolved polymer for
danazol solutions containing PVP, HPMC, and HPMC-AS (10 μg/mL polymer
concentration).20 However, in this study, no difference was observed for danazol alone,
relative to in the presence of polymers. It was speculated that the kinetics of drug-rich
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droplet formation in systems without polymer was slower than in solutions containing a
polymers, which could lead to an overestimation of the concentration at which LLPS was
observed experimentally, for solutions analyzed immediately after generation of a
supersaturated solution. In other words, there is a finite time for the nucleation of
danazol-rich droplets. To investigate this, danazol solutions of different concentrations
were analyzed over short time periods, using the fluorescent probe method. Figure 3-5
shows the pyrene I1/I3 ratio vs danazol concentration at different analysis times; 15
seconds (the original method),20 1 minute, and after 5 minutes; these times are all before
the samples start crystallizing ~10-15 min.

The formation of drug-rich droplets is

indicated by a drop in the pyrene I1/I3 peak ratio. Clearly, at 15 seconds, the formation of
drug-rich droplets is picked up at a higher danazol concentration (between 10 and 14
μg/mL; 13 μg/mL was the value previously reported),20 relative to when the analysis was
conducted after 1 and 5 minutes, where a danazol-rich phase was detected at around 8
μg/mL. This result is interesting in that we have analyzed >20 compounds using this
approach, and have never observed any time dependent effects of this nature previously.
Additional experiments with pre-dissolved PVP revealed similar results, while
solutions containing either HPMC and HPMC-AS showed no kinetic effects and showed
changes in the pyrene I1/I3 ratio around 7-8 μg/mL of danazol, regardless of the time of
acquisition.

3.5.4 Induction Time Experiments.
In order to explore the kinetic properties of the colloidal solutions, and the impact
of polymers thereof, crystallization induction times were determined for solutions

137
containing 15 µg/mL of danazol. Based on the NTA information shown in Figure 3-2
these solutions contain >3 x 109 droplets per mL. Figure 3-6 shows examples of how the
polymers impact induction times, prolonging the duration of supersaturation in all cases,
albeit to different extents. PVP is the least effective polymer, while HPMCAS is highly
effective at preventing crystallization.
The impact of polymer concentration on induction times was also assessed with
results summarized in Figure 3-7. Danazol, in the absence of polymer crystallizes within
10-15 minutes. In the presence of all three polymers, crystallization was inhibited for a
significant amount of time ranging from 30 minutes to 6 hours.

At a polymer

concentration of 1 μg/mL, the polymers have equal impact on crystallization inhibition,
and only marginally extend induction times. However, at polymer concentrations of 10
μg/mL and above, a clear differentiation between polymers is apparent, with HPMCAS
being much more effective than PVP and HPMC. Increasing the polymer concentration
from 10 to 1000 μg/mL did not extend induction times any further.

3.5.5

Zeta-potential of the Drug-rich Droplets.

To better understand the concentration dependent interactions of polymer with the
droplets, zeta-potential measurements were conducted. Zeta-potential is related to the
surface charge and characteristics of the particles being measured.28

Figure 3-8

summarizes the zeta-potential values measured for the various danazol-polymer systems
studied.
The zeta-potential of danazol droplets in the absence of polymer was found to be
–8.1 mV. The addition of PVP and HPMC, both neutral polymers, increased the zeta-
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potential, consistent with the polymers interacting with the surface and reducing the
negative charge. The extent of the increase in zeta potential was concentration dependent
for PVP, with less concentration dependence observed for HPMC The addition of
HPMC-AS, a negatively charged polymer at the pH employed, decreased the zetapotential, with the extent of the decrease being dependent on the concentration of the
polymer.

3.5.6

Particle Size Analysis on Drug-rich Droplet Phase.

Both DLS and NTA size analysis was performed on danazol nanodroplets in order
to evaluate the impact of polymer type and amount on droplet size. The size analysis
data is summarized in Figure 3-9.
The mean particle diameter (z-diameter), as determined from DLS analysis,
suggested that the droplet size decreased from around 350 nm with no/low polymer
concentrations to around 150 nm with the highest polymer concentrations, with a similar
trend being observed for all the polymers studied. However, the NTA data did not show
any obvious trends in mean droplet size as a function of polymer concentration, with the
mean droplet size being determined as ~200-250 nm. Particle size analysis results on a
sample with the same particle size distribution are known to sometimes vary when using
DLS versus NTA. DLS is highly biased towards the presence of a few larger particles
within a single sample as compared to NTA. This bias skews the distribution and
calculated mean particle size towards the larger particles.29 Therefore, it appears that in
the presence of a polymer, the formation of some larger droplets, probably through
coalescence, is reduced, resulting in less bias using DLS. Because NTA tracks individual
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particles, a few large particles do not have such a major contribution to the mean particle
size, since they are statistically less likely to be analyzed.

3.6

Discussion

When considering solubility enhancing formulations, an important distinction
should be noted between supersaturation and solubilization. Solubilization increases the
drug concentration in solution by increasing the equilibrium solubility, and therefore does
not increase the solute chemical potential. These systems will not precipitate unless
dilution of the solubilizing component occurs. In a supersaturated solution, the solute
concentration is higher than the concentration that can be achieved by dissolving the
crystalline material. Supersaturating drug delivery systems, such as amorphous solid
dispersions (ASDs), are thus designed to increase aqueous drug concentrations beyond
that achievable with formulations containing crystalline drug. This can lead to highly
supersaturated solutions which are inherently meta- or unstable, because the chemical
potential of the solute is increased relative to the reference crystal form, thus there is a
thermodynamic driving force for crystallization. However, supersaturated solutions are
regarded favorably for drug delivery, since they have improved mass transport across
membranes because of the increase in the amount of free drug molecules as compared to
solubilized systems, where the overall concentration is increased, but not the membrane
transport rate.30-32
Two potential phase transitions can occur in supersaturated solutions depending
on the degree of supersaturation, and the properties of the solute, namely LLPS followed
by crystallization, or crystallization.15, 20, 33-39 LLPS can only occur in solutions where a
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certain supersaturation is exceeded, whereas crystallization can theoretically occur once
the concentration exceeds the threshold concentration for primary nucleation. The
potential phase transitions are summarized in Figure 3-10. Differentiating these
transitions is important, since crystallization will deplete the supersaturation until
ultimately, the equilibrium solubility is reached. In contrast, LLPS, while leading to a
new phase, will result in a system that is still supersaturated. This motivates our interest
in the properties of the colloidal solutions resulting from LLPS. LLPS can be understood
at a more fundamental level by referring to the phase diagram shown in Figures 3-11.
For a system that exhibit a miscibility gap, as shown by the free energy of mixing
versus composition diagram in Figure 3-11,39 there is an upper limit of concentration
(supersaturation for samples that are crystalline at the temperature of analysis) of the drug
in the aqueous phase that can be achieved (and likewise, an upper limit of water than can
be present in the drug-rich phase), and when this concentration is reached, the system
becomes unstable and will undergo spinodal decomposition, where phase separation is
spontaneous and unavoidable.12, 25, 39 For spinodal decomposition, the activation energy
for formation of a new phase is zero, so demixing is spontaneous. For a solution of drug
and water, the resultant two phase system consists of a drug-rich phase and a water-rich
phase, with compositions of xab and xba. These binodal points (XAB and XBA) indicate the
boundary concentrations at which two phases can coexist. Concentrations between the
binodal and spinodal points can undergo phase separation so long as the activation energy
of forming the new phase is overcome. If the melting point of the drug is above the
experimental temperature, these two phases exist in metastable equilibrium, and
crystallization can occur at any point, since the system is supersaturated. Both the binodal
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and spinodal points can be experimentally estimated if crystallization is sufficiently slow
to enable the measurements to be made.12, 37, 40
This phase diagrams can also help with a potential explanation for the data shown
in Figure 5. From a theoretical perspective, if the difference between the binodal and
spinodal points is large enough, and the activation energy for formation of the new phase
is high, then supersaturation with respect to the binodal composition (i.e. the amorphous
solubility, point XAB) might be observed, with phase separation being observed at a
higher concentration than the amorphous solubility. For most systems studied to date,
little supersaturation has been observed with respect to the co-existence concentration,12,
23

whereby phase separation is observed immediately this concentration is exceeded.

However, in the case of danazol, we speculate that the difference seen in Figure 3-5,
where the concentration at which LLPS occurs shows some time dependency, is due to a
higher energy barrier for formation of the new phase, as compared to other systems that
have been studied. This allows the amorphous solubility to be exceeded during the
experiments where supersaturation is generated very rapidly. The addition of polymer
seemingly lowers this activation barrier, yielding lower experimental LLPS
concentrations than for the drug alone at short time frames. The polymer is most likely
interacting with the droplets, lowering the surface tension needed to form the new
interface necessary for LLPS. The measured zeta-potential of droplets provides support
for this supposition since the polymers clearly interact with the droplet surface (Figure 38).
One of the primary goals of this study was to evaluate the impact of polymers
commonly used in ASD formulations on thermodynamic properties of supersaturated
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solutions as well as the kinetics of subsequent phase transformations. Excipients that
influence the crystalline solubility or the concentration at which LLPS is observed impact
the solute thermodynamic activity, which in turn can impact mass transport across a
membrane. For example a second component that mixes with the drug-rich phase will
decrease the amorphous solubility, and thus lower the maximum achievable
supersaturation. Additives that increase crystalline solubility through complexation or
micellar solubilization, can “consume” the supersaturation, reducing the amount of free
drug and the rate of transport across a membrane.22 For the danazol-polymer systems
studied herein, there are no significant changes to the crystalline solubility (Table 3-1).
Furthermore, the experimentally determined amorphous solubility (based on the HPLC
data, Table 3-2) in the presence of polymer was independent of the amount of polymer
added and also showed good correlation with the theoretically estimated amorphous
solubility of danazol which was 7.8 µg/mL. Most definitively, the flux values for the
systems were the same regardless of polymer type or amount, whereby the maximum
achievable flux was the same as that for drug alone. Flux values are highly dependent on
the thermodynamic activity of the solute, rather than on concentration per se, and hence
this data supports the supposition that the polymers do not impact the ability of danazol
to undergo membrane transport.30

These data thus confirm that significant amounts of

polymer do not mix with the danazol-rich phase (if it did, the danazol activity would be
reduced), and hence there is no change in the amorphous solubility. In other words, the
polymers evaluated do not solubilize the drug, and do not spontaneously mix with the
amorphous drug-rich droplets formed via LLPS water, and thus allow highly
supersaturated solutions to be generated. This is in contrast to recent observations with
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resveratrol, where cellulose polymers were found to result in a considerable solubilization,
reducing the extent of supersaturation achieved in the systems.
Although the thermodynamics properties of danazol solutions appear to be
unaltered by the presence of polymers, up to a concentration of 1 mg/mL, the polymers
have a dramatic effect on crystallization kinetics, as observed previously for numerous
drug-polymer systems.26, 41-44 To expand on previous studies with danazol,20 the impact
of polymer concentration on the induction times was evaluated for two phase solutions,
i.e. solutions that had undergone LLPS. Interestingly, for all polymers studied, the largest
gain in crystallization inhibition was achieved upon increasing the concentration from 1
to 10 μg/mL, with fairly minimal increases in induction times upon increasing the
polymer concentration to 1 mg/mL. This highlights the extremely small quantities of
polymers needed to achieve crystallization inhibition, even in the presence of a drug-rich
phase. Although there was evidence from the zeta potential measurements that all three
polymers interacted with the surface of the danazol droplets, HPMC-AS was clearly the
most effective crystallization inhibitor, while PVP was least effective. Furthermore, even
though the zeta potential continued to decrease with increasing polymer concentration for
HPMC-AS containing solutions, suggesting that more polymer was present at the droplet
surface at higher polymer concentrations, this did not translate into increased
crystallization inhibition.

3.7

Conclusions

Supersaturated danazol solutions were found to undergo LLPS in the presence
and absence of three model polymers, leading to the formation of a drug-rich phase with
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a mean size of around 200-250 nm. The onset concentration of LLPS was found to be in
good agreement with the estimated amorphous solubility. Common amorphous solid
dispersion polymers did not alter either the crystalline or amorphous solubility of danazol,
and hence did not compromise the improved membrane transport rates afforded by
maximally supersaturated solutions. However, the dissolved polymers did dramatically
improve the stability of supersaturated solutions to crystallization, with polymer
concentrations as low as 1 μg/mL showing inhibitory effects. Characterizing the solution
phase behavior of supersaturated solutions of poorly water soluble drugs in the presence
of polymers is essential to understand enhancing formulations such as amorphous solid
dispersions.
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3.8

Tables

Table 3-1. Crystalline Solubility (μg/mL) of Danazol in the Presence and Absence of
Polymers at 25°C, n=3, Errors Equal One Standard Deviation
Amount of Polymer

PVP

0 μg/mL

HPMC

HPMC-AS

0.9 ± 0.1

1 μg/mL

0.8 ± 0.2

0.9 ± 0.3

1.0 ± 0.2

10 μg/mL

1.3 ± 0.4

2.2 ± 0.5

1.1 ± 0.4

100 μg/mL

1.1 ± 0.4

1.7 ± 0.8

1.4 ± 0.6

1000 μg/mL

1.2 ± 0.3

2.1 ± 1.0

1.3 ± 0.5
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Table 3-2. LLPS Concentrations (µg/mL) via multiple analytical techniques. Error shows
one standard deviation for the UV Extinction and HPLC data (n=3). Fluorescent Probe
and NTA data were also performed in triplicate, whereby the concentration increment
was 1 μg/mL. The error for these systems was less than the concentration increment.

DNZ Only
1 µg/mL
10 µg/mL
100 µg/mL
500 µg/mL
1000 µg/mL

8.3 ± 1.0
8.2 ± 0.4
8.3 ± 0.5
7.8 ± 0.5
8.1 ± 0.6
8.2 ± 0.2

Fluorescent
Probe
8
8
8
8
7
7

1 µg/mL
10 µg/mL
100 µg/mL
500 µg/mL
1000 µg/mL

8.7 ± 1.2
8.1 ± 0.6
8.0 ± 0.3
7.7 ± 0.4
7.8 ± 0.3

8
8
8
7
8

HPMC

PVP

System

1 µg/mL
10 µg/mL
100 µg/mL
500 µg/mL
1000 µg/mL

UV Extinction

HPMC-AS

8.5 ± 0.3
9
7.6 ± 0.9
8
7.7 ± 0.8
8
8.0 ± 0.5
8
8.1 ± 0.2
7
*could not be determined due to danazol crystallization

HPLC

NTA

n/d*
8.2 ± 0.6
8.9 ± 0.2
9.1 ± 0.5
8.8 ± 0.4
8.6 ± 0.6

8
8
7
8
8
8

8.6 ± 0.7
8.3 ± 0.8
8.3 ± 0.5
8.1 ± 0.8
8.5 ± 1.2

8
7
8
7
7

8.1 ± 0.4
8.0 ± 0.3
8.2 ± 0.4
8.4 ± 0.6
8.2 ± 0.3

8
8
7
7
7
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3.9

Figures

Figure 3-1. Nanoparticle Tracking Analysis images taken from danazol solutions below
8μg/mL (a), at 8μg/mL (b), and above 8μg/mL (c) the measured LLPS concentration.
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Figure 3-2. The numbers of particles tracked per mL of solution as a function of danazol
concentration obtained from NTA.
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Figure 3-3. Danazol flux versus the concentration of danazol in the donor chamber of the
diffusion cell. The flux of solutions containing 10 μg/mL of polymer is also shown, as is
the flux of a suspension containing crystalline danazol, (solubility of 0.9 μg/mL).
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Figure 3-4. Maximum flux values from supersaturated danazol solutions (15 μg/mL) with
different concentrations of pre-dissolved polymer.
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Figure 3-5. Pyrene I1/I3 peak ratio as a function of danazol concentration whereby the
solutions were evaluated at different time points following the addition of danazol to the
solution.
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Figure 3-6. UV Absorbance data used to determine the crystallization induction time of
supersaturated danazol solutions (added danazol concentration of 15 µg/mL) in the
presence and absence of 10 µg/mL polymer.
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Figure 3-7. Average crystallization induction times of supersaturated danazol solutions
(15 µg/mL) with varying amounts of pre-dissolved polymer.
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Figure 3-8. The zeta-potential of the drug-rich droplets formed via LLPS in danazolpolymer systems.
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Figure 3-9. The mean size of the drug-rich danazol droplets as determined from DLS (left)
and NTA (right) measurements.

Figure 3-10. Potential phase transitions within a supersaturated aqueous drug systems.
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Figure 3-11. Free energy of mixing diagram depicting a miscibility gap which can result
in LLPS in aqueous-drug systems (adapted from Steele and Deneau).39
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CHAPTER 4. DISSOLUTION AND PHASE BEHAVIOR OF DANAZOL
AMORPHOUS SOLID DISPERSIONS

4.1

Abstract

Amorphous solid dispersions are currently being widely investigated for the
ability increase the apparent solubility of poorly soluble drugs.

The dissolution of

amorphous solid dispersions results in supersaturated solutions which can result in
multiple phase transitions. The purpose of this chapter was to investigate the dissolution
profiles of amorphous solid dispersions with a model drug, danazol, with regards to
supersaturation and precipitation. Solution concentration vs time profiles were generated
in parallel with a fluoresecent probe technique to identify the nature of the precipitation
(liquid-liquid phase separation or crystallization). Dispersions instantaneously exhibited
liquid-liquid phase separation upon surpassing the amorphous solubility and subsequently
undergo crystallization after a period of time (1-8 hours) depending on the polymer used
in the dispersion.

A side-by-side diffusion cell was used to assess the extent of

supersaturation and the maximum free-drug concentration achieved from the dissolution
of amorphous solid dispersions. Supersaturation equivalent to the amorphous solubility
was achieved for multiple drug-polymer systems, resulting in a maintained
supersaturation during dissolution until crystallization. Overall, the dissolution profiles
of were impacted by the creation of a second drug-rich droplet phase through liquidliquid

phase

separation

prior

to

crystallization

in

solution.
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4.2

Introduction

Amorphous solid dispersions (ASDs) are of great interest as a formulation
strategy because upon dissolution, they can increase the effective solubility and
consequently, in many instances, the bioavailability of poorly soluble drug molecules.1-5
The increase in effective solubility is due to the thermodynamically higher energy state of
the amorphous form relative to the crystalline form.6 The formulation of robust ASDs
can be challenging due to the risk for transformation to the crystalline form. 7 Polymers
are added to ASDs to stabilize against crystallization both during storage8 and
dissolution.9-12

The inhibition of crystallization during dissolution enables a

supersaturated solution to be generated under non-sink dissolution conditions.10,

12

Furthermore, there is mounting evidence that a second phase transition can occur in
highly supersaturated drug solutions prior to crystallization known as liquid-liquid phase
separation (LLPS).13, 14
LLPS occurs in solutions when the addition of a drug into an aqueous solution
surpasses a boundary concentration above which the drug is no longer miscible with the
aqueous phase.15 The LLPS boundary concentration can also be defined as the
amorphous solubility.2, 13, 16-18 The amorphous solubility has been described previously
and is the maximum increase in apparent solubility upon dissolution of an amorphous
form relative to the crystalline form when no crystallization occurs.2-5 The amorphous
solubility can be estimated from the thermodynamic properties of the crystalline and
amorphous drug, and LLPS determination experiments have shown that the estimated
amorphous solubility is generally in good agreement with the experimentally observed
LLPS onset concentration.16 A system will only undergo LLPS following creation of a
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highly supersaturated system where crystallization is inhibited.

The presence of a

polymer can thus inhibit crystallization, creating the potential to enter a solution
concentration regime where LLPS can occur; this has been demonstrated for
supersaturated solutions of nifedipine where the LLPS concentration cannot be achieved
in the absence of an effective crystallization inhibitor.19,

20

However, the tendency of

ASDs formulated with different polymers and at different drug loading to undergo LLPS
upon dissolution has not been evaluated to date.
In the current study, we examined the dissolution behavior of ASDs containing
the model drug, danazol. The solution behavior of danazol has been extensively studied
with regards to supersaturation and precipitation.18, 21, 22

Methods to detect both LLPS

and crystallization in danazol-polymer solution systems were previously developed and
employed in the current study to evaluate the dissolution of ASDs formulated using three
model polymers; polyvinyl pyrrolidone (PVP), hydroxypropylmethyl cellulose (HPMC),
and HPMC acetate succinate (HPMC-AS). Using these methods, the tendency of the
various formulations to lead to LLPS upon dissolution was evaluated and correlated to
the level of supersaturation generated as well as the expected amorphous solubility.

4.3

Materials

Danazol was purchased from Euroasia Chemicals (Euroasia Ltd., China), pyrene
and polyvinylpyrrolidone (PVP) K29/32 were purchased from Sigma-Aldrich (St. Louis,
MO),

while

hydroxypropylmethyl

cellulose

(HPMC)

606

grade

and

hydroxypropylmethyl cellulose acetate succinate (HPMC-AS) MF grade were supplied
by Shin-Etsu (Shin-Etsu Chemical Co., Ltd., Tokyo, Japan). Methanol, acetonitrile, and
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dichloromethane were purchased from Macron Chemicals (Phillipsburg, New Jersey).
The aqueous medium used in all experiments was 10 mM pH 6.8 phosphate buffer.
Pyrene was added to solutions at a concentration of 2 µM for fluorescence measurements.

4.4
4.4.1

Methods

Preparation of Amorphous Solid Dispersions

Amorphous solid dispersions (ASDs) of polymer-danazol systems consisting of
90:10, 70:30, and 50:50 polymer-drug ratios were prepared via spin-coating. Stock
solutions of danazol and polymer (PVP, HPMC, and HPMC-AS) were prepared by
dissolving a total weight of 1 g of polymer-drug in 10 mL of ethanol and
dichloromethane (1:1 w/w). A few drops of each stock solution were dropped onto the
center of a 22 mm by 22 mm No 1. glass cover slip and prepared on a KW-4A two-stage
spin coater (Chemat Technology, Northridge, CA) by rotating at 500 and 1000 rpm for 10
and 30 s, respectively. The process was repeated on the same cover slip sample to build
layers of the ASD and achieve the desired ASD weight, adequate for dissolution
experiments. The amount of drug added to the system was optimized to create theoretical
maximum solution concentrations between 20-30 μg/mL for all experiments, which is
above the expected LLPS onset concentration of 8 μg/mL. Polarized light microscopy
was used to determine if there was any crystallinity in the resultant ASD films. All ASDs
of 90:10 and 70:30 polymer-drug were completely void of any crystalline domains. The
50:50 ASDs contained some crystalline domains approximately equivalent to 10% of the
surface area of the films.
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4.4.2

Parallel UV Spectroscopy and Fluorescence Spectroscopy during Dissolution of
Danazol ASDs
The phase behavior of the solutions generated during dissolution of the ASDs was

monitored using ultraviolet (UV) and fluorescence spectroscopy. For the fluorescence
spectroscopy, the fluorescence emission spectrum of an environmentally sensitive probe,
pyrene, was monitored, after adding pyrene to the solution at a concentration of 2 μM.
ASD films were added to 50 mL of aqueous buffer solution (10 mM phosphate buffer,
pH 6.8) and the solution was stirred using a magnetic stirrer at 300 RPM. UV spectra
were obtained from this solution using an in situ fiber optic dip probe with a path length
of 1 cm coupled to a SI Photonics UV/vis spectrophotometer (Tucson, Arizona).
Calibration standards of danazol, prepared in methanol (1-100 μg/mL), resulting in a
linear standard curve (r2 > 0.999) were used to estimate the concentration evolution
during the dissolution measurements.

UV signal intensity was processed at two

wavelengths: the maximum absorbance wavelength of danazol (288 nm) and at 350 nm,
where no absorption is observed. UV spectra were obtained every 60 s. Fluorescence
spectroscopy was also obtained on the same samples. 2 mL aliquots were extracted and
analyzed at various time points using a Shimadzu RF-5301pc Spectrofluorometer (Kyoto,
Japan). The excitation wavelength was 332 nm, and the emission spectrum was collected
at 0.2 nm intervals from 350 to 420 nm. The excitation slit width was 10 nm, while the
emission slit width was 1.5 nm.
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4.4.3

Flux Measurements via Diffusion Cell Apparatus

A side-by-side diffusion cell (PermeGear, Inc. Hellertown, Pennsylvania) was
used to evaluate the relationship between flux rate, donor solution concentration, and
LLPS using a method developed previously.17 A regenerated cellulose membrane with a
MWCO of 6–8 KDa was used to separate the donor and receiver chambers. Both the
donor and receiver compartments hold a maximum of 200 mL and are separated by a
circular opening with a diameter of 30 mm. Both compartments were filled with 200 mL
of buffer and the ASD samples were placed inside a Tissue-Tek biopsy cassette (Sakura
Finetek USA, Inc., Torrance, California) with 1 mm pores to prevent fragments of the
ASD from interfering with the UV dip probe (Figure 4-1). A fiber optic dip probe with a
path length of 2 cm coupled to a SI Photonics UV/vis spectrophotometer was submerged
in the receiver side, while a second dip probe with a path length of 1 cm was submerged
in the donor side. UV spectra were obtained every 15 s. for 60 minutes for both sides.
Concentration versus time profiles for the receiver compartment were generated
and analyzed to determine the flux of the drug from the donor compartment to the
receiver compartment. The flux (J) is determined from the change in mass per unit time
(dM/dt) and can be obtained from the slope of the concentration versus time profile using
linear regression. The relationship between flux and the properties of the drug and the
diffusion cell is shown by the following equation:

𝐽=

𝑑𝑀 𝐷𝑆𝑎
=
𝑑𝑡
ℎ𝛾𝑚

Equation 4-1
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The flux is dependent on the diffusion coefficient (D), the membrane crosssectional area (S), the solute thermodynamic activity (a), the activity coefficient of the
solute in the membrane (γm), and the thickness of the membrane (h). Furthermore, the
activity (𝑎) can be estimated using the following equation:

𝑎=

𝐶𝑖
= 𝑆𝑖
𝐶𝑆

Equation 4-2
where Ci is the experimental free drug concentration and CS is the crystalline equilibrium
solubility.17 The activity estimated as the ratio of the free drug concentration to the
crystalline equilibrium solubility can also be defined as the supersaturation (Si). A
solution with a free drug concentration below the crystalline solubility, and therefore no
crystallization, has a supersaturation <1.

In contrast, a solution with a free drug

concentration greater than the crystalline solubility has a supersaturation >1, and a
thermodynamic driving force for crystallization. Substituting Equation 4-2 into Equation
4-1 shows that the supersaturation is directly proportional to the flux:

𝐽 = 𝑆𝑖 ∗

𝐷𝑆
ℎ𝛾𝑚

Equation 4-3
For this study, S, D, γm , and h, are constants using the experimental setup
described above. A linear standard curve (r2 > 0.997) was created by determining the
flux using known solutions of known supersaturation spanning the crystal and amorphous

170
solubilities, in the donor cell. The flux of the drug upon dissolution of the ASDs was
then determined and used to calculate the maximum supersaturation achieved by
dissolution of the different ASD formulations. This value was compared with both the
UV absorbance data and the amorphous solubility of the drug.

4.4.4

Nanoparticle Tracking Analysis

Nanoparticle tracking analysis was used to characterize the precipitate formed
upon dissolution of the ASD films. 1 mL samples of each solution were withdrawn at the
desired time point and analyzed using a NanoSight LM10 from Malvern Instruments
(Westborough, MA) equipped with nanoparticle tracking analysis software. The LM10
was equipped with a 75 mW green (532 nm) laser and a temperature controlled flow
through cell stage. Samples were analyzed at 25°C for 30 seconds and camera settings
were held constant throughout all experiments (screen gain = 2.0, camera level=7). The
detection threshold upon analysis was also held constant (5) for all experiments along
with camera gain (10.0).

4.5
4.5.1

Results and Discussion

Dissolution Behavior of Danazol ASDs

Supersaturated solutions of poorly water soluble drugs, such as those that can
result from the dissolution of ASDs under non-sink conditions, have been shown to
undergo different types of phase transitions, which are often collectively termed
precipitation.15, 21, 23 Formation of a new phase (i.e. precipitation) is normally regarded as
a negative consequence because it results in a loss of supersaturation.24

However,
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precipitation is an ambiguous term which doesn’t discriminate between the formation of
crystalline and amorphous phases. Formation of a disordered, drug-rich (amorphous)
phase by the process of LLPS, which yields a turbid solution, results in a two phase
system which is supersaturated relative to the crystalline form. Furthermore, it has been
suggested that the drug-rich phase, which is in metastable equilibrium with the bulk
aqueous solution, can act as a drug reservoir, replenishing drug that it absorbed and
maintaining supersaturation at a constant value during absorption as long as the two
phases are present and crystallization is avoided.17 In contrast, crystallization will lead to
depletion of supersaturation. Consequently, in order to evaluate the dissolution behavior
of ASDs and understand their in vivo advantage, it is essential to evaluate their solution
thermodynamics and phase behavior.
Although the dissolution of ASDs has be extensively studied9-12,

25

, the

occurrence of LLPS during the dissolution process is not typically investigated, although
several studies have noted the generation of colloidal species during the dissolution
process.10, 13, 26 Ilevbare demonstrated that the formation of these colloidal species during
the dissolution of an ASD could be rationalized based on understanding the LLPS
phenomenon.13 In other words, when the ASD dissolves to a concentration higher than
the amorphous solubility, a new drug-rich phase is evolved. This was demonstrated by
dissolving a high polymer loading ASD of ritonavir formulated with PVP. However,
there are several outstanding questions about the link between ASD dissolution and LLPS.
These include understanding if LLPS leading to the formation of a drug-rich phase only
occurs when a certain polymer is used to formulate the dispersion, and if the
drug:polymer ratio in the dispersion has an impact on the tendency of the system to
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undergo LLPS. In an attempt to address these questions, we applied several orthogonal
techniques, previously applied to study LLPS in supersaturated solutions generated by
antisolvent addition, to evaluate the non-sink dissolution behavior of danazol ASDs
formulated with different polymers and drug loadings.
The dissolution profiles of ASDs formulated with HPMCAS, HPMC or PVP with
polymer-drug ratios of 90:10 are shown in Figure 4-2.

Figure 4-2 shows the apparent

concentration as a function of time for the various dispersions, obtained using UV
spectroscopy. Also shown in the plot are fluorescence data, obtained by monitoring the
emission spectrum of the environmentally sensitive fluorescence probe, pyrene.
Monitoring the solution concentration reveals that the dissolution is rapid from the ASD,
and the concentration quickly exceeds the crystalline solubility (0.9 μg/mL), forming a
supersaturated solution, and then exceeds the amorphous solubility (8 μg/mL). Above the
amorphous solubility, the UV determined concentration values are not reliable due to the
expected presence of nanospecies that both absorb and scatter light.27 The ratio of the
intensities of the first and the third peaks (I1/I3) of the pyrene emission spectrum provide
information about the local environment of the probe.28 When this ratio is high (~1.9),
the probe is in a hydrophilic, aqueous environment. This is the value of the I1/I3 ratio at
the beginning of the experiment. Once the dissolved danazol concentration reaches a
certain value, it can be seen that the I1/I3 ratio decreases. This is consistent with the
preferential interaction of the probe with a newly formed disordered drug-rich phase.
Hence the probe is in a more hydrophobic average environment and a decrease in the I1/I3
ratio is observed. The supersaturation generated by the ASD dissolution does persist
indefinitely. The supersaturation duration depends on the polymer used to formulate the
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ASD. In the case of the PVP dispersion (Fig 4-2a), after approximately 75 min, a
decrease in UV absorption is observed, indicating that crystallization has commenced and
the supersaturation is being depleted due to the formation and growth of crystalline
danazol particles. Concomitantly, the I1/I3 ratio increases, indicating that the disordered
drug-rich phase is lost as crystals form. For the HPMC and HPMCAS dispersions,
corresponding changes in concentration and pyrene I1/I3 ratio were observed at 300 and
360 minutes respectively as shown in Fig 4-2b and 4-2c.
All of the 70:30 dispersions and the 50:50 PVP:danazol dispersions showed
similar dissolution profiles, whereby the amorphous solubility was exceeded, and LLPS
was detected based on the response of the pyrene probe. Differences in the duration of
supersaturation were observed, as for this 90:10 dispersions, and these will be discussed
in more detail below. However, dispersions formulated with HPMC and HPMC-AS at the
50:50 ratio resulted in different dissolution profiles. Figure 4-3 shows an example of
each of the 50:50 systems. Both the HPMC and HPMC-AS systems have a much slower
initial dissolution and lack the characteristic drop in apparent solution concentration
indicative of crystallization. The fluorescence data for the 50:50 dispersions with HPMC
(Fig. 4-3b) showed a decrease in the pyrene I1/I3 ratio when the solution concentration
exceeds 8 μg/mL. In contrast, 50:50 dispersions with HPMC-AS (Fig. 4-3c) do not reach
the amorphous solubility and only a small decrease in the I1/I3 ratio is observed which
probably can be attributed to the interaction of the probe with undissolved dispersion; this
is most noticeable only at long time periods.
The phase behavior of the various ASDs following dissolution, in terms of the
duration of supersaturation, and the concentration where LLPS was observed, is
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summarized in Figure 4-4. The data for the solutions generated from ASD dissolution is
also compared to phase behavior of danazol supersaturated solutions produced by
antisolvent addition,22 in order to understand how predictive these simple screening
experiments are with regard to ASD performance.
The crystallization induction times for solutions resulting from ASD dissolution
are similar to the solutions generated by anti-solvent addition, which contain the
corresponding polymer, pre-dissolved, with the exception of the 50:50 HPMC and
HPMC-AS dispersions which do not show desupersaturation over the duration of the
experiments. It can be seen that all systems containing PVP had the shortest induction
times, whereas the HPMC-AS systems have the longest induction times. Hence in the
case of danazol ASDs, the solution screening experiments predict the stability of the
ASDs during dissolution quite well. The concentration at which LLPS occurs was also
estimated from the ASD dissolution data by evaluating the apparent solution
concentration at the time point when the pyrene I1/I3 ratio showed a dramatic decrease. It
should be noted that time resolution of the fluorescence measurements is not as high as
the UV measurements since the former were obtained using manual sampling. With this
caveat in mind, it can be seen that fluorescence measurements indicate that LLPS has
occurred for all dispersions bar the 50:50 HPMC-AS dispersions, when the concentration
exceeds 6-10 μg/mL. This concentration range is in good agreement with the estimated
amorphous solubility (8 μg/mL), as well as the results obtained for solutions generated by
anti-solvent addition.
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4.5.2

Characterization of the Drug-Rich Droplets Formed upon Dissolution.

The dissolution of the danazol ASDs resulted in supersaturated drug solutions and
the results obtained with the fluorescence probe, pyrene, suggested that LLPS occurred,
leading to the formation of a drug-rich phase. NTA was employed to study the size
characteristics of the new phase and this information is summarized in Table 4-1 for
solutions produced by both anti-solvent addition and ASD dissolution.
The average sizes observed for the drug-rich phase generated by dissolution from
the ASD are similar to those obtained following creation of the drug-rich phase by antisolvent addition.22 The concentrations shown are determined based on the number of
“particles” tracked by the instrument and the sample volume analyzed.

The

concentration of scattering species is slightly higher for solutions evolved from ASD
dissolution relative to the anti-solvent addition samples, and this can be readily accounted
for by a difference in the mass of the drug added (15 μg/mL for anti-solvent addition vs
20-30 μg/mL for the ASD samples). Figure 4-5 shows single frames taken from the
video capture of the NTA scattering data, showing the light scattered by the drug rich
phase produced upon the dissolution of 90:10 polymer-drug ASDs as compared to a
solution which was supersaturated using anti-solvent addition. Samples were analyzed at
a time point corresponding to a maximum in apparent solution concentration profile, and
therefore provide a snapshot of the size and amount of the drug-rich phase formed via
LLPS, prior to the onset of crystallization. The clear presence of a scattering phase of
submicron dimensions in highly supersaturated solutions provides additional support for
our conjecture that these systems can undergo an amorphous precipitation (LLPS)
without eliminating the overall amorphous solubility advantage. This was explored
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further by exploring the mass transport properties of the solutions derived from ASD
dissolution.

4.5.3

Comparison of Maximum Free-Drug Concentration for Different ASD
formulations

In order to fully understand the thermodynamics and ultimate impact LLPS, the
free-drug concentration, or the maximum achievable supersaturation resulting from ASD
dissolution must be determined. UV absorption data provides a good starting point for
measuring the apparent solution concentration, in particular during the early stages of
dissolution but the presence of nano-sized drug droplets (such as those formed during
LLPS) can impact the observed concentrations. Nano-sized particles have been shown to
both scatter and absorb ultra-violet light, thus leading to an overestimate of molecularly
dissolved drug based on the UV absorption data.27 Filtering may not be particularly
useful since some or all of the drug-rich phase may pass through the filter, and the
filtration process may induce crystallization.29 The free drug concentration, in other
words the amount of molecularly dissolved drug, is important since it directly dictates the
supersaturation in the system, which not only provides the thermodynamic driving force
for crystallization, but also leads to enhanced membrane transport. When LLPS occurs,
the free drug concentration reaches a maximum, and thus all the ASDs which showed
LLPS should show the same flux. Therefore, in order to assess relative supersaturation
achieved by dissolving the various dispersions, the flux of the drug molecule across a
membrane was measured to determine the free-drug concentration. As described above
and shown previously,17,

22

flux is directly proportional to the free-drug solution
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concentration or more precisely, the solute thermodynamic activity (i.e. supersaturation),
rather than total concentration. To perform these experiments, the dissolution of danazol
ASDs was performed in the donor compartment, creating a supersaturated solution, and
the concentration evolution in both the donor and receiver cells was monitored as a
function of time. The flux was determined from the slope of the concentration versus
time plot in the receiver cell once the concentration in the donor cell reached a maximum
and prior to crystallization, as shown in Figure 4-6.
At steady state, the flux is directly proportional to the free drug concentration in
the donor compartment (Equation 4-3). The supersaturation can then be calculated and
evaluated from the flux data upon dissolution. Figure 4-7 provides a summary of the
maximum supersaturation observed for the various ASDs and comparable anti-solvent
experiments, calculated from the flux data shown in Table 4-2.
All of the ASDs with the exception of the 50:50 HPMC-AS:danazol system
dissolved to produce the same maximum supersaturation, which, within experimental
error, had a free drug concentration equivalent to the amorphous solubility, 8 μg/mL.
This was despite the fact that the concentration registered in the donor compartment was
higher based on the UV absorption data, and in terms of the amount added. All of these
dispersions underwent LLPS, giving rise to two phase solutions. As discussed previously,
the amorphous solubility represents the maximum achievable supersaturation and free
drug concentration. This has been shown previously for solutions created by anti-solvent
addition,22 but is confirmed here for supersaturated solutions generated by ASD
dissolution. Thus, when ASDs undergo LLPS, the maximum in membrane transport rate
is achieved. In contrast, the system that did not show any evidence of LLPS, the 50:50
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HPMC-AS:danazol dispersion, shows a lower maximum flux than the other systems,
consistent with a lower overall supersaturation (see Figure 4-3c, which shows the
dissolution profile and Figure 4-7 which shows the lower supersaturation achieved by this
system). These results thus clearly demonstrate the potential benefits of formulating an
ASD system such that LLPS occurs on dissolution, since this process, which leads to a
maximally supersaturated solution, correlates with the maximum in transport rate. Clearly
in the case of danazol, quite high drug loadings can be achieved such that LLPS is still
observed upon dissolution; up to 30% drug loading for all of the polymers investigated.
However, the even higher drug loading systems (50% drug loading) show much slower
dissolution rates, and even if they do exceed threshold concentration for LLPS, this was
only observed at long time frames, and hence these formulations might not be expected to
perform comparably in terms of membrane transport in vivo.

4.6

Conclusions

The data outlined above provides strong evidence that for these specific drugpolymer system, LLPS occurs prior to crystallization which reaches a maximum
supersaturation regardless of how it is created (anti-solvent vs ASD dissolution). The
presence of LLPS during dissolution is a critical result in the understanding of ASD
dissolution.

LLPS occurs at the amorphous solubility limit or can otherwise be

considered the miscibility limit of the drug in an aqueous system. These results reveal
that above a critical concentration, additional drug that dissolves from the amorphous
formulation will phase separate into drug-rich droplets, effectively creating a maximum
concentration limit in solution of drug.13, 16-18, 30

Overall, the presence of precipitation
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upon ASD dissolution does not always result in a loss of supersaturation, but rather could
maintain supersaturation through the formation of the drug-rich droplets formed during
LLPS.
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Tables

Table 4-1. Nanoparticle Tracking Analysis of solutions generated by surpassing the
amorphous solubility prior to crystallization.
Mean Particle Size

Concentration

(nm)

(109 particles/mL)

15 μg/mL*

267 ± 67

3.2 ± 0.6

100:15 μg/mL*

223 ± 64

2.9 ± 0.2

90:10 ASD

256 ± 75

4.1 ± 0.8

100:15 μg/mL*

233 ± 74

3.0 ± 0.5

90:10 ASD

284 ± 81

4.5 ± 0.7

100:15 μg/mL*

205 ± 63

2.9 ± 0.6

90:10 ASD

246 ± 54

4.4 ± 0.5

System
DNZ
PVP:DNZ

HPMC:DNZ

HPMC-AS:DNZ

* Pre-dissolved polymer and supersaturation created using anti-solvent method from
previous study.22 The added danazol concentration was 15 μg/mL and the polymer
concentration was 100 μg/mL.

181
Table 4-2. Flux and free drug concentration data from ASD dissolution and
supersaturated danazol solutions.
Flux (μg/min)

System

Free Drug Concentration
(μg/mL)

Crystalline

0.006 ± 0.001

1.0 ± 0.1

15 μg/mL*

0.115 ± 0.009

8.1 ± 1.2

90:10 ASD

0.103 ± 0.006

7.3 ± 1.0

50:50 ASD

0.099 ± 0.008

7.1 ± 1.1

100:15 μg/mL*

0.100 ± 0.008

7.2 ± 1.1

90:10 ASD

0.124 ± 0.009

8.7 ± 1.2

HPMC:DNZ 50:50 ASD

0.129 ± 0.016

9.1 ± 1.6

100:15 μg/mL*

0.110 ± 0.004

7.8 ± 0.9

90:10 ASD

0.117 ± 0.010

8.2 ± 1.2

50:50 ASD

0.073 ± 0.003

5.4 ± 0.8

100:15 μg/mL*

0.116 ± 0.009

8.2 ± 1.2

DNZ

PVP:DNZ

HPMCAS:DNZ

* Pre-dissolved polymer and supersaturation created using anti-solvent method from
previous study.22
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Figures

Figure 4-1. Schematic of diffusion cell apparatus setup. The donor cell and receiver cell
both hold a maximum of 200 mL.
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Figure 4-2. Dissolution profiles of 90:10 polymer-drug ASDs with PVP (a), HPMC (b),
and HPMC-AS (c). The apparent solution concentration was measured using UV
absorbance (left axis and black squares) while the presence of LLPS was monitored using
pyrene as a fluorescent probe (right axis and open blue circles).
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Figure 4-3. Dissolution profiles of 50:50 polymer-drug ASDs with PVP(a), HPMC (b),
and HPMC-AS (c). The apparent solution concentration was measured using UV
absorbance (left axis and black squares) while the presence of LLPS was monitored using
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Figure 4-5. NTA images of a supersaturated danazol solution (15 ug/mL DNZ) via antisolvent method (left) and supersaturated danazol solution via dissolution of PVP-DNZ
90:10 ASD (right).
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CHAPTER 5. SUPERSATURATION IN THE PRESENCE OF CRYSTAL SEEDS
DURING THE DISSOLUTION OF AMORPHOUS SOLID DISPERSIONS

5.1

Abstract

The supersaturation profiles of solutions created from the dissolution of amorphous
solid dispersions (ASDs) were examined in this chapter. Previously, supersaturation was
observed from the dissolution of a model drug-polymer ASD (danazol-HPMC) with
presence of crystalline seeds within the dispersion prior to dissolution. In this study, the
degree of supersaturation and the crystallization behavior of several drug systems in the
presence and absence of crystalline drug introduced in multiple ways was measured using
UV spectroscopy and a side-by-side diffusion. A plateau supersaturation was observed
for all systems, but the plateau value varied depending on how crystalline material was
introduced into the system.

Furthermore the relationship between dissolution rate,

nucleation induction time, and crystal growth was evaluated with respect to these systems.
Ultimately, supersaturation was achieved and maintained upon dissolution of an ASD in
the presence of crystalline drug and the degree of supersaturation was dependent on the
presence of polymer and the origin of the crystalline drug (i.e ASD matrix or native
crystals).
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5.2

Introduction

Amorphous solid dispersions (ASD) are of great interest for the formulation of
poorly water soluble drugs because of their ability to dissolve and generate supersaturated
solutions resulting in enhanced uptake from the GI tract, and ultimately, increased
bioavailability.1-10

The solutions resulting from ASD dissolution under non-sink

conditions are supersaturated with respect to the crystalline drug and thus have a
tendency to crystallize; crystallization must be inhibited for a sufficient period of time in
order to utilize the increases in apparent concentration.9-13 In the absence of rapid
crystallization, the upper limit of achievable supersaturation is dictated by the amorphous
solubility, and the dissolution of ASDs can lead to liquid-liquid phase separation, leading
to the formation of a colloidal, drug-rich phase in metastable equilibrium with the bulk
aqueous solution.8, 14-19
Understanding the different phase transformations is critical to understanding the
likely in vivo performance of supersaturated solutions.

Precipitation is generally

regarded as a negative consequence of generating a supersaturated solution 20-23 and much
effort is being directed towards employing additives for solution crystallization
inhibition.11-15,

18, 24-27

Formulations are being developed to maintain supersaturation

upon dissolution by selection of a polymer which both stabilizes the amorphous drug in
the solid state (i.e. in the solid dispersion) and is able to inhibit crystallization from
solution.
One area of research that has received little attention, is the impact of trace
crystallinity on the ability of ASDs to dissolve and generate supersaturated solutions.
Trace crystallinity may be present in the ASD as a result of residual crystals remaining or
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evolving during processing,28 or may form during storage.29 To date, most research on the
impact of crystals on the duration of supersaturation has focused on adding native
crystals to supersaturated solutions and monitoring desupersaturation profiles.11, 30 In
these studies, it was noted that addition of crystalline material resulted in rapid
desupersaturation which could be hindered by the addition of polymers, but not
completely prevented. In a previous study, it was noted that, somewhat surprisingly, the
dissolution of an ASD consisting of a 50:50 ratio of danazol and hydroxypropylmethyl
cellulose (HPMC) yielded a supersaturated solution that persisted for 24 hours, despite
the ASD containing up to 10% crystalline material, formed during ASD preparation.8 The
goal of the current study was to evaluate the dissolution behavior of ASDs in the
presence of crystalline material in terms of the supersaturation behavior. The crystalline
material was either formed in the ASD during the production process, or was added
separately in the form of crystal seeds. Crystal growth rate measurements in the presence
and absence of polymers were used to aid in interpretation of the results.

5.3

Materials

Danazol was purchased from Euroasia Chemicals (Euroasia Ltd., China), and
hydroxypropylmethyl cellulose (HPMC) 606 grade was supplied by Shin-Etsu (Shin-Etsu
Chemical Co., Ltd., Tokyo, Japan). Methanol, acetonitrile, and dichloromethane were
purchased from Macron Chemicals (Phillipsburg, New Jersey). The aqueous medium
used in all experiments was 10 mM pH 6.8 phosphate buffer.
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5.4
5.4.1

Methods

Preparation of Danazol Systems

Amorphous solid dispersions (ASDs) of polymer-danazol systems consisting of
90:10 and 50:50 polymer-drug ratios were prepared via spin-coating. Stock solutions of
danazol and HPMC were prepared by dissolving a total weight of 1 g of polymer-drug in
10 mL of ethanol and dichloromethane (1:1 w/w). A few drops of each stock solution
were dropped onto the center of a 22 mm by 22 mm No 1. glass cover slip and prepared
on a KW-4A two-stage spin coater (Chemat Technology, Northridge, CA) by rotating at
500 and 1000 rpm for 10 and 30 s, respectively. The process was repeated on the same
cover slip sample to build layers of the ASD and achieve the desired ASD weight,
adequate for dissolution experiments. The amount of drug added to the system was
optimized to create theoretical maximum solution concentrations between 20-30 μg/mL
for all experiments, which is above the expected LLPS onset concentration of 8 μg/mL,
and therefore can generate maximally supersaturated solutions under non-sink dissolution
conditions.
Samples containing crystalline danazol were produced by adding 1 mg of
crystalline danazol to 10 mL of deionized water and drying. Polymer-coated crystalline
danazol was produced by adding 1 mg of crystalline danazol to 10 mL of deionized water
containing 100 μg/mL of pre-dissolved HPMC. The polymer-coated crystalline danazol
was prepared in order to investigate the impact of polymer adsorption/coating of
crystalline danazol on its ability to grow in a supersaturated danazol solution. A few
drops of the suspensions containing crystalline drug were placed on a glass cover slip and
the water was allowed to evaporate off at room temperature within a desiccator
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containing Drierite (97% anhydrous calcium sulfate and 3% cobalt (II) chloride) for 12
hours. Samples were then placed in a vacuum oven at room temperature for 12 hours to
evaporate off any residual solvent.

5.4.2 Polarized Light Microscopy
Polarized light microscopy (PLM) was used to analyze the prepared ASD films to
assess the extent of crystallization using the approach developed by Van Eerdenburgh et
al,31, 32 and to characterize the amorphous or crystalline nature of any precipitates formed
upon dissolution of the films. The films were assessed by direct evaluation of the ASD
films formed on the coverslips, while the dissolution media was analyzed by collecting a
small aliquot of the solution at the desired time point and placing 2-3 drops of the sample
solution onto a quartz slide containing a depression. All samples were imaged using a
Nikon Eclipse E600 Pol microscope with a 10X objective and the NIS-Elements software
package (Version 2.3; Nikon Company, Tokyo, Japan).

5.4.3

Flux Measurements

A side-by-side diffusion cell (PermeGear, Inc. Hellertown, Pennsylvania) was
used to determine the extent of supersaturation generated during ASD dissolution by
determining danazol flux. Both the impact of crystal seeds present within the ASD matrix
of an ASD as well as the effect of pure crystalline drug added separately during ASD
dissolution were investigated. A regenerated cellulose membrane with a MWCO of 6–8
KDa was used to separate the donor and receiver chambers. Both the donor and receiver
compartments hold a maximum of 200 mL and are separated by a circular opening with a
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diameter of 30 mm. A temperature of 25°C was maintained using a Julabo MA water
bath connected to the jacketed vessels of the side-by-side diffusion cell.

Both

compartments were filled with 200 mL of buffer and all samples were placed inside a
Tissue-Tek biopsy cassette (Sakura Finetek USA, Inc., Torrance, California) with 1 mm
pores to prevent fragments of the ASD from interfering with the UV dip probe (Figure 51).

A fiber optic dip probe with a path length of 2 cm coupled to a UV/Vis

spectrophotometer (SI Photonics Inc., Tucson, Arizona) was used on the receiver side,
while a second dip probe with a path length of 1 cm was used on the donor side. UV
spectra were obtained every 30 s. for 240 min. for both sides. Measurements were
obtained at two wavelengths; the maximum UV absorbance wavelength of 288 nm for
danazol and at a wavelength of 350 nm where danazol shows no absorption; scattering
due to a new phase can be monitored at 350 nm.
Concentration versus time profiles for the receiver compartment were generated
to determine the flux of the drug from the donor compartment to the receiver
compartment, as described in previous studies.8, 19, 33 Concentration versus time profiles
for the donor compartment were also generated.

5.4.4

Seeded Desupersaturation Experiments

The desupersaturation profile of supersaturated danazol solutions following
seeding was evaluated in order to evaluate bulk crystal growth rates in buffer and in the
presence of pre-dissolved polymer. Samples consisted 50 mL of aqueous buffer, stirred at
300 RPM and held at 25°C using a jacketed beaker fed by a Julabo MA water bath. The
UV wavelengths of 288 nm (UV maximum absorbance of danazol) and 350 nm
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(extinction of solution) were collected every 30 s. for 240 min. Supersaturation was
created using an anti-solvent method. A small aliquot of danazol dissolved in methanol
was added to buffer to create specific supersaturations, in order to study the relationship
between supersaturation and crystal growth rates, using similar supersaturation values to
those obtained during ASD dissolution. The crystalline samples were again prepared on
glass coverslips and placed inside biopsy cassettes to prevent large fragments from
interfering with the UV dip probe. Crystalline danazol was added one minute after
generation of the supersaturation and concentration was monitored continuously using the
dip probe.

5.5
5.5.1

Results

Characterization of the ASDs and Crystalline Samples

Polarized light microscopy revealed no crystalline material present in ASDs with a 90:10
polymer:drug ratio. However, small crystals were present in the 50:50 ASDs. Figure 5-2
shows representative polarized light microscope images. The crystals present in the
50:50 ASD samples are relatively small in size and cover approximately 10% of the
surface area of the sample on the glass cover slip. The crystalline samples and polymercoated crystalline samples showed uniform coverage on the coverslip.

5.5.2

Dissolution Behavior of ASDs with Crystal Seeds Present

The properties of the solutions generated by ASD dissolution, with respect to
crystallization and supersaturation, were examined using the side-by-side diffusion cell
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apparatus. The dissolution profiles (non-sink dissolution conditions) of a variety of ASD
samples are shown in Figure 5-3.
The 90:10 ASDs all showed a fast initial dissolution rate, however the maximum
concentration reached varied depending if crystalline material was present. The 90:10
ASD without crystalline material dissolved to reach the highest apparent concentration,
which was just above the amorphous solubility of 8 μg/mL. Adding some of the partially
crystallized 50:50 ASD resulted in a somewhat slower dissolution rate after about 45 min,
but the maximum apparent solution concentration was similar to that obtained for the
90:10 ASD. In contrast, samples which contained native crystalline drug (both with and
without a polymer coating) impacted the dissolution of the 90:10 ASD, resulting in a
much lower plateau concentration, ~4-5 ug/mL, i.e. only approximately half of that
reached for the other 90:10 samples. The partially crystallized 50:50 dispersion had a
much slower dissolution rate and reached a maximum concentration of around 4 μg/mL
at 240 min.
The free drug concentration at the plateau of the profiles observed in Figure 5-3
was determined using flux measurements in order to determine the extent of
supersaturation in the different solutions.

Previously it has been shown that the

supersaturation of the solution in the donor compartment can be determined based on the
flux across a membrane and knowledge of the crystalline solubility.8, 33 Figure 5-4 shows
the maximum supersaturation obtained by dissolving each system and the relationship to
the crystalline and amorphous solubilities of danazol.
The extent of supersaturation achieved upon the dissolution of the 90:10 spiked with the
partially crystallized 50:50 ASD was similar to that of the pure 90:10 ASD, and equal to
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the amorphous solubility. These systems may have surpassed the amorphous solubility,
as shown previously,8 and have reached the maximum free-drug solution and the overall
supersaturation by undergoing liquid-liquid phase separation. The remaining systems
(90:10 ASD + crystalline danazol, 90:10 ASD + 50:50 physical mixture of HPMC and
crystalline danazol, and 50:50 ASD) all has similar plateau supersaturation values (Si ~
5.5). Control experiments with crystalline danazol led to a supersaturation value of 1.0 ±
0.1 after 4 hours, as expected.

5.5.3

Seeded Desupersaturation

During the dissolution of ASDs, supersaturated solutions were generated and
maintained for at least 4 hours even in presence of crystalline seeds of danazol. Seeded
and unseeded experiments were therefore carried out at two supersaturation levels (8
µg/mL and 5 µg/mL), corresponding to the plateau levels obtained in the ASD
experiments, with pre-dissolved HPMC (100 µg/mL) in the solution. Figure 5-5 shows
the apparent solution concentration over 4 hours with and without seeding.
Supersaturated danazol solutions in absence of any polymer crystallized rapidly
and the apparent solution concentration decreased to the crystalline solubility within 1020 minutes, both in the presence and absence of seeds (as shown in Chapter 2). In the
presence of pre-dissolved polymer, unseeded danazol solutions at either supersaturation
show very little desupersaturation over a 4 hr period. At the higher initial supersaturation
(8 µg/mL), the addition of crystalline seeds results in an initial rapid desupersaturation
that tails off such that the concentration is around 5 μg/mL after 4 hr. At the lower initial
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supersaturation, addition of seeds results in very slow desupersaturation over the time
frame of the experiment, and a minimal decrease in solution concentration.

5.6

Discussion

The solution concentration-time profile, and hence the subsequent supersaturation,
following dissolution of an ASD will depend on the interplay between the dissolution rate
of the amorphous formulation and kinetics of crystallization.

Davey and Cardew

investigated and modeled the solvent-mediated phase transformation of a metastable
polymorph to the stable form and their approach can be used to better understand the
behavior of the systems under evaluation in our study.34 They pointed out that the
supersaturation-time profile of a metastable system undergoing transformation to a stable
form is dependent on the solubility difference between the two forms, the dissolution rate
of the metastable polymorph and the crystal growth rate of the stable polymorph.34 This
approach results in a model whereby the supersaturation profile over time can be
predicted based on these two rates. Following this same logic, for an amorphous solid
dispersion, the maximum supersaturation will be dictated by the ratio of the amorphous
and crystalline solubility values, while the supersaturation time profile will depend on the
rate of dissolution of the amorphous solid dispersion, the lag time for nucleation of the
crystalline phase and the growth rate of the crystals.
The dissolution rate of the metastable phase and growth rate of the stable phase
will increase and decrease the supersaturation respectively. Thus, it has been shown that
a plateau supersaturation can be achieved for some duration of time while the dissolution
of the first phase is relatively fast as compared to the growth of the second phase, before
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ultimately decreasing towards the equilibrium concentration when the metastable form
has dissolved completely.34 The supersaturation at which this plateau occurs will depend
on the relationship between dissolution rate and crystal growth rate.

During ASD

dissolution, if the crystal growth rate is much greater than the dissolution rate, the plateau
supersaturation will be low. This scenario would be expected to occur in an ASD system
where crystals are present and the polymer is a poor inhibitor of crystal growth at the
supersaturation generated by the dissolving amorphous form. Hence the advantage of
using an amorphous formulation is lost because the crystal growth rate is too high.
However, as the growth rate decreases (by adding an effective crystal growth inhibitor),
then a higher supersaturation plateau can be achieved. When the dissolution rate is much
greater than the growth rate, the supersaturation can reach the maximum free-drug
concentration which is dictated by the amorphous solubility, above which the system
with spontaneously form a drug-rich phase via liquid-liquid phase separation (LLPS).14, 16
This drug-rich phase will enable the supersaturation to be maintained at the maximum
value since it will act as a reservoir to replace drug removed by crystallization. 19 Given
sufficient time, the solution concentration of all systems will decrease towards the
equilibrium concentration.
The supersaturation profiles of the HPMC-danazol ASD systems studied herein
were greatly influenced by the presence of crystalline seeds. The dissolution of the
different systems (Figure 5-3) resulted in different plateau supersaturation depending on
the presence or absence of crystalline material, as well as how the crystalline material
was generated.

In the absence of crystal seeds, the plateau supersaturation upon

dissolution of a 90:10 HPMC-danazol ASD is equal to the amorphous solubility or
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maximum free-drug concentration. This system has a high dissolution rate and previous
work has shown that the crystallization induction time is greater than 3 hours in the
presence of HPMC.33

Hence only the dissolution rate dictates the time until the

maximum supersatuation is achieved, while the maximum supersaturation observed is
determined by the amorphous solubility. When crystal seeds evolved from within the
solid dispersion matrix (50:50 ASD) were added to the 90:10 ASD, the maximum
supersaturation was again achieved, suggesting that the added crystals grew more slowly
than the dissolution of the amorphous material. In contrast, native danazol crystals
appeared to grow faster, leading to a plateau supersaturation value approximately half
that observed for the crystal free dispersion, although the system was still supersaturated
with respect to the crystalline solubility. This system has reached a pseudo-equilibrium
between the dissolution of the ASD and the growth of drug crystals.
By removing the dissolution step, and instantaneously generating a supersaturated
solution, the ability of different types of crystalline material to induce desupersaturation
can be evaluated. Interestingly, the crystals evolved from the ASD were much less
effective at inducing desupersaturation at a supersaturation equivalent to the maximum
achievable supersaturation relative to with native crystals or polymer-coated native
crystals (Figure 5-4). These experiments confirm the importance of the growth rate in
determining the overall supersaturation profile. Furthermore, the driving force for crystal
growth also needs to be considered since clearly at a lower supersaturation, all types of
crystal seeds were relatively ineffective at inducing desupersaturation – in other words, in
the presence of a pre-dissolved polymer, crystal growth was effectively inhibited over the
timescale of the experiment. This is an important observation since it demonstrates that
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supersaturation can persist in the presence of crystalline seeds, albeit at a lower level than
the amorphous solubility. The observation that polymers are more effective crystal
growth inhibitors has been noted previously.11, 15 The growth rate data correlate very well
with the ASD dissolution data and help to explain the levels of supersaturation observed
in the seeded dissolution studies.
Figure 5-6 shows desupersaturation profiles in the presence of crystalline seeds
with and without the presence of polymer.

The addition of polymer dramatically

decrease the crystal growth rate while the system without polymer has a fast growth rate
and the solution rapidly reaches the equilibrium solubility. The dissolution of ASDs
above in the presence and absence of crystalline seeds is similar to the supersaturation
profile shown here. The ability to maintain supersaturation is thus reliant on ability of the
polymer to inhibit crystal growth. Furthermore, when trying to evaluate the impact of
residual crystallinity on the performance of an ASD, it may be important to produce the
crystalline material in the presence of the polymer, since the ASD evolved crystals may
have a different impact of crystallization relative to native crystals.

5.7

Conclusions

The ability to produce sustained supersaturation following ASD dissolution is
dependent on the interplay between dissolution and crystallization kinetics. Adding
crystal seeds to the ASD and monitoring the dissolution profile enables the effectiveness
of a given polymer at inhibiting crystal growth at relevant supersaturations to be
evaluated. Surprisingly, the crystal seed history influences the concentration-time profiles
generated during ASD dissolution and should be considered when designing experiments
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to test the impact of residual crystallinity. In order to successfully formulate ASDs to
yield maximum supersaturation, the interplay between dissolution rate and crystallization
kinetics should be thoroughly evaluated.
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5.8

Figures

Figure 5-1. Schematic of diffusion cell apparatus setup. The donor cell and receiver cell
both hold a maximum of 200 mL.

Figure 5-2. Polarized light microscopy images of danazol systems prepared on glass
coverslips; 50:50 HPMC-danazol ASD (left), pure crystalline danazol (center), and
polymer-coated crystalline danazol (right).
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Figure 5-3. Dissolution Profiles of HPMC-danazol ASDs. There were five drug systems
investigated; 90:10 ASDs (black squares), 50:50 ASDs (blue triangles), 90:10 ASDs +
50:50 ASDs (red circles), 90:10 ASDs + crystalline danazol (purple triangles), and 90:10
ASDs + polymer-coated crystalline danazol (green diamonds).
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Figure 5-4. Maximum observed supersaturation of solutions following dissolution of
different ASDs systems containing some crystalline drug. The crystalline solubility of
danazol is 0.9 μg/mL (Si = 1) and the amorphous solubility of danazol is 8 μg/mL (Si =
8.8).
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Figure 5-5. Apparent UV concentrations of supersaturated danazol solutions in the
presence and absence of crystal seeds. All solutions above have pre-dissolved HPMC
polymer (100 µg/mL HPMC).
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Figure 5-6. Desupersaturation profiles of supersaturated danazol solutions in the
presence and absence of polymer and crystal seeds. The polymer concentration was 100
µg/mL for systems indicated to include polymer.
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CHAPTER 6. SUMMARY OF RESEARCH AND FUTURE WORK
RECOMMENDATIONS

The focus of this thesis was to investigate phase behavior in the supersaturated
solutions formed during the dissolution of amorphous solid dispersions, specifically for a
poorly water soluble model drug, danazol.

The following is a chapter by chapter

summary of the important results observed followed by recommendations for future
studies.

6.1

Influence of Polymers on the Supersaturation Behavior of Danazol

In chapter 2, the phase behavior of supersaturated danazol solutions was
investigated in the presence and absence of polymers. Upon surpassing a threshold
concentration (amorphous solubility), these systems undergo liquid-liquid phase
separation (LLPS), creating a disordered drug-rich droplet phase and a drug-lean aqueous
phase. LLPS was observed prior to crystallization in supersaturated danazol solutions by
using multiple analytical techniques; UV spectroscopy, the use of a fluorescence probe,
and second harmonic generation. The addition of polymers (PVP, HPMC, and HPMCAS) inhibited crystallization and prolonged the presence of LLPS in systems above the
amorphous solubility, to varying degrees. This study serves as a fundamental basis of the
thermodynamic properties of danazol in an aqueous solution.

Additionally, the

development of the analytical techniques, outlined in this chapter, to detect and
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differentiate between LLPS and crystallization, was vital to studying the complex
phase behavior within supersaturated drug solutions in later studies.

6.2

Characterization of the Drug-Rich Droplet Phase formed via Liquid-Liquid Phase
Separation
The drug-rich droplets formed during LLPS, and the effect of polymers on the

solution properties, were investigated and characterized in chapter 3.

The onset

concertation of LLPS was found to correlate with the estimated amorphous solubility and
the mean droplet size was found to be in range of 200-250 nm. The addition of polymers
did not influence the onset concentration of LLPS but it was shown to have an effect on
the kinetics of both crystallization and LLPS. The polymers provided crystallization
inhibition within the solution, allowing for prolonged stability of the two-phase colloidal
system prior to crystallization. The ability to evaluate the colloidal solutions formed
upon supersaturation is pivotal to be able to study the behavior of solutions generated
from solubility enhancing formulations, such as amorphous solid dispersions.

6.3

Dissolution Behavior of Danazol Amorphous Solid Dispersions

In Chapter 4, the application of methods and techniques developed in chapters 2
and 3 for the characterization of the dissolution of amorphous solid dispersions (ASDs)
of danazol and three polymers (PVP, HPMC, HPMC-AS) is described. The non-sink
dissolution behavior was also evaluated using a side-by-side diffusion cell to determine
the free-drug solution concentration and overall effect of LLPS on passive membrane
transport.
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During dissolution, the ASDs studied in this chapter undergo LLPS upon
surpassing the amorphous solubility of danazol.

The two-phase system persists for

prolonged periods of time before ultimately crystal nucleation and growth occurred,
depleting the supersaturation. These results are significant because it reveals that there is
an upper limit for the miscibility of a drug in solution, regardless of how the
supersaturation is generated (anti-solvent or ASD dissolution). This miscibility is crucial
for understanding the mechanics behind ASD formulations and the overall upper-limit of
supersaturation for a given drug molecule. The addition of a polymer which can inhibit
the kinetics of crystallization without influencing the thermodynamics (solubility) of the
drug allows for stabilization of the drug-rich droplet phase, which behaves as a reservoir
for maintaining the supersaturation of the aqueous phase.

6.4

Influence of Crystal Seeds on Supersaturation via Dissolution of Amorphous Solid
Dispersions
In chapter 4, the dissolution of ASDs resulted in supersaturated solutions that

undergo LLPS. This result was significant in itself, however, some of the ASD systems
which generated supersaturated solutions showed the presence of crystal nuclei formed
during the preparation. The purpose of chapter 5 was to investigate the presence of
crystal seeds during the dissolution of danazol ASDs and the impact they have on
supersaturation. Side-by-side diffusion experiments and desupersaturation experiments
were executed to determine the relationship between the dissolution rate, delay in crystal
nucleation, and crystal growth rate.
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The dissolution of ASDs in the presence of crystals still yielded supersaturated
solutions, albeit at different levels. Dissolution of systems with no crystals or with
crystals formed within the matrix of the solid dispersion created supersaturated solutions
equal to the maximum solution concentration (amorphous solubility) as seen in chapters
2-4. However, the introduction of crystalline material (both native and polymer-coated)
resulted in lower solution concentrations, although solutions were still supersaturated. It
is suggested that the ability of the polymer to decrease the crystal growth rate along with
a high dissolution rate of the ASD results in a pseudo-equilibrium between the
dissolution of the ASD and growth of crystalline drug; creating a supersaturation plateau
of possibly several hours before crystal growth dominates and the concentration drops
towards the crystalline equilibrium.

The significance of creating prolonged

supersaturated solutions in the presence of crystalline drug cannot be overstated. It is
hypothesized that the ability to formulate and control drug supersaturation could depend
on the interplay between polymer selection, dissolution rate, and the presence of
crystalline material in the dispersion.

6.5

Future Work Recommendations

The observations surrounding the phase behavior of ASDs upon dissolution creates
some intriguing ideas to formulate future studies around. The following is a brief list of
avenues for which more investigation is suggested pertaining to these systems.


The influence of polymers plays a key role in influencing the kinetics of these
systems. Understanding drug-polymer interactions within the solution is crucial
and most be investigated to fully understand the mechanisms by which the
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polymers influence these systems during dissolution. Additionally, only a few
polymers were studied within the scope of this thesis research and the ability to
screen many polymers is vital because currently there are very few models to
predict drug-polymer interactions both in the solid-state and in solution.


Danazol was chosen as a model drug to study because it is poorly soluble in water
and previously had some interesting precipitation results. The methods developed
within the scope of this thesis can and should be applied to multiple drug systems.
Studying similar drugs to danazol, such as other steroid derivatives like estradiol
and mevastatin, would produce interesting insight into the role chemical
properties have on the thermodynamics of ASD formulations.



In chapter 2, second harmonic generation (SHG) was used to qualitatively
determine the crystallinity in solution of supersaturated danazol systems. This
tool is unique in its ability to detect only crystalline material in complex samples.
Analyzing the solution behavior during dissolution of ASDs with SHG would
enable the creation of crystal growth profiles in solution. Furthermore, proof-ofconcept experiments have shown promise in detecting crystalline material in
turbid media, something which cannot be done accurately with current techniques
(UV spectroscopy, dynamic light scattering, etc.). Thus, a natural progression
would be to study similar drug-polymer systems using SHG in biorelevant media
which cannot be studied using current spectroscopy methods. The ability to
determine if crystalline material is present or not in turbid media, such as FaSSIF,
FeSSIF, or Ensure Plus (a dissolution media for a fed meal), would be pivotal in
creating experiments that could result in in Vitro/in Vivo correlation.
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Lastly, LLPS formed in highly supersaturated drug solutions influences the
amount of free-drug available for uptake. The drug-rich droplet phase formed
during LLPS was investigated in chapter 3, but further work is necessary to fully
understand the consequences of such a phase transformation in solution.
Additionally, the impact LLPS can have on passive membrane transport was
explored in chapters 3 and 4, but it would be interesting to investigate the impact
of LLPS on transport across complex membranes, as it would provide valuable
information which would more closely mimic a situation occurring during
dissolution of ASDs within the GI tract.
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